1
|
Sijbesma JWA, van Waarde A, Klooster A, Kion I, Slart RHJA, Lammertsma AA, Giacobbo BL, Boersma HH, Dierckx RAJO, van Goor H, Bakker SJL. Caloric restriction reduces proteinuria in male rats with established nephropathy. Physiol Rep 2024; 12:e15942. [PMID: 38439743 PMCID: PMC10912948 DOI: 10.14814/phy2.15942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/15/2024] [Accepted: 01/15/2024] [Indexed: 03/06/2024] Open
Abstract
Reducing proteinuria is a crucial approach in preventing kidney function loss. Previous preclinical studies indicated that caloric restriction (CR) imposed at a young age protects against age-related proteinuria. However, these studies have not explored CR in established renal disease. Therefore, this study aimed to investigate the impact of CR on established proteinuria. Rats, aged 12 ± 2 weeks, were administered 2.1 mg/kg of Adriamycin. Six weeks after injection, protein excretion was measured, and a [13 N]ammonia positron emission tomography (PET) scan was conducted to assess kidney perfusion. After 7 weeks rats were divided into four groups: ad libitum (AL) and CR groups fed either a 12% or a 20% protein diet. All groups were treated for 12 weeks. Blood pressure was measured and a second PET scan was acquired at the end of the study. The animals subjected to CR exhibited a 20.3% decrease in protein excretion (p = 0.003) compared to those in the AL groups. Additionally, blood pressure in the CR group was 21.2% lower (p < 0.001) than in the AL groups. While kidney function declined over time in all groups, the 20% CR group demonstrated the smallest decline. Thus CR effectively reduces urinary protein excretion and lowers blood pressure in rats with established proteinuria.
Collapse
Affiliation(s)
- J. W. A. Sijbesma
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - A. van Waarde
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - A. Klooster
- Department of PathologyPathologie FrieslandLeeuwardenThe Netherlands
| | - I. Kion
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - R. H. J. A. Slart
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
- Department of Biomedical Photonic Imaging, Faculty of Science and TechnologyUniversity of TwenteEnschedeThe Netherlands
| | - A. A. Lammertsma
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - B. Lima Giacobbo
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - H. H. Boersma
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
- Department of Clinical Pharmacy and PharmacologyUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - R. A. J. O. Dierckx
- Department of Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - H. van Goor
- Department of Pathology and Medical BiologyUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| | - S. J. L. Bakker
- Department of NephrologyUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
| |
Collapse
|
2
|
Verweij NJF, Ter Wee M, De Jongh J, Zwezerijnen GCJ, Yaqub M, Van Schaardenburg D, Voskuyl A, Lems W, Lammertsma AA, Boers M, Van der Laken CJ. OP0189 MACROPHAGE PET/CT IMAGING OF THE FEET CAN CONTRIBUTE TO EARLY PREDICTION OF THERAPY OUTCOME IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Treat-to-target strategies for rheumatoid arthritis (RA) have shown significant improvements in therapy outcomes. Nevertheless, it usually takes a minimum of 12 weeks before clinical assessment of treatment response can be made. Quantitative positron emission tomography (PET) has shown potential to predict clinical response at a very early stage in the treatment in RA patients.(1) In particular, macrophage imaging by [11C]-(R)-PK11195 PET allows for highly sensitive and specific imaging of RA disease activity.(2,3)Objectives:To determine whether quantitative assessment using [11C]-(R)-PK11195 PET/CT imaging at 0-2 weeks is associated with subsequent clinical response to therapy with methotrexate and step-down prednisolone (COBRA-light) therapy in therapy-naive RA patients.Methods:Whole body [11C]-(R)-PK11195 PET/CT scans were performed at baseline and after two weeks of treatment in thirty-five clinically active and therapy-naive RA patients and at least two clinically inflamed joints. All patients were DMARD-naïve and received medication according to the COBRA-light schedule. (4) Clinical follow up with DAS44 assessment was performed at 0, 2 and 13 weeks of treatment. PET/CT scans were visually assessed by two experienced readers blinded to clinical data and quantitatively analyzed using in-house software. Regions of interest (ROIs) with a fixed size per joint (on both visual PET positive and negative joints) were placed on shoulders, elbows, hips, knees and hand and feet joints, with the CT-scan as anatomical reference. Standardized uptake values (SUVs) normalized for body weight were calculated in these ROIs to determine the amount of tracer uptake per joint. SPSS version 22.0 was used to perform regression analyses. The sum of visually positive joints and the average SUV in hand joints, feet joints and all joints in the body were compared with DAS44 scores.Results:Included patients were mostly male (51%) and aged 54 ± 12. Baseline DAS44 was 3.2 ± 1.0; all but one of the thirty-five patients demonstrated visually enhanced tracer uptake in one or more joints on PET/CT. A total of 171 (out of 1470) joints (12%) were visually PET positive at baseline. Over 90% of PET positive sites were located either in the wrists (15%), small hand joints (37%), or small feet joints (40%; Figure 1A). After 2 weeks, the number of PET positive joints had decreased to 100, with the highest decrease in quantitative uptake in feet joints (Figure 1B). Notably, both visual and quantitative PET data at baseline and differences between baseline and 2 weeks did not correlate with DAS44 at 13 weeks (DAS44-13wks). However, at 2 weeks, the average SUV in the feet (SUVfeet-2wks) – but not average SUVhands-2wks or average SUVtotalbody-2wks – was significantly correlated with DAS44-13wks (R2 = 0.14, p = 0.04). DAS44-2wks and SUVfeet-2wks both contributed independent information to the prediction DAS44-13wks (combined R2 = 0.297, p < 0.01).Figure 1.Changes in [11C]-(R)-PK11195 uptake in MTP joints of a RA patient, before (A) and 2 weeks after initiation of COBRA light treatment (B).Conclusion:Quantitative macrophage PET assessment in feet joints after 2 weeks of COBRA light treatment in early RA patients correlates with clinical response after 3 months of treatment. This correlation further increases when combined with the DAS44 score at 2 weeks. Therefore, quantitative, non-invasive macrophage PET/CT, especially when combined with early clinical assessment, may be useful for early assessment of response to treatment. Further studies will help optimize timing and focus of the PET examination in prediction of treatment response.References:[1]Elzinga EH, et al. J Nucl Med. 2011; 52(1):77-80.[2]Van der Laken CJ et al. Arthritis Rheum. 2008 Nov;58(11):3350-5.[3]Gent YY, et al. J Rheumatol. 2014; 41: 2145-52[4]Den Uyl D, et al. Ann Rheum Dis. 2014;73(6):1071-8.Disclosure of Interests:Nicki J.F. Verweij: None declared, Marieke ter Wee: None declared, Jerney de Jongh: None declared, Gerben C.J. Zwezerijnen: None declared, Maqsood Yaqub: None declared, Dirkjan van Schaardenburg: None declared, Alexandre Voskuyl: None declared, WIllem Lems Speakers bureau: Pfizer, Galapagos, Eli Lilly, Amgen, UCB, Curaphar, Consultant of: Pfizer, Galapagos, Eli Lilly, Amgen, UCB, Curaphar, Grant/research support from: Pfizer, Adriaan A. Lammertsma Consultant of: Roche, Maarten Boers Consultant of: Novartis, BMS, Pfizer, Conny J. van der Laken Consultant of: Novartis, Pfizer, Abbvie, UCB, BMS, GSK, Galapagos, Grant/research support from: Novartis, Pfizer, Abbvie, UCB, BMS, GSK, Galapagos
Collapse
|
3
|
Caruana CJ, Karenauskaite V, Mornstein V, Vano E, Pace E, Lammertsma AA, Maas AJJ, Bert C, Byrne B, Colgan N, Essers M, Isidoro J, Koniarova I, Makridou A, Pesznyak C, Rønde HS, Winiecki J. A generic curriculum development model for the biomedical physics component of the educational and training programmes of the non-physics healthcare professions. Phys Med 2021; 85:32-41. [PMID: 33964550 DOI: 10.1016/j.ejmp.2021.04.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 03/23/2021] [Accepted: 04/14/2021] [Indexed: 11/19/2022] Open
Abstract
The objective of the study was the construction of a generic curriculum development model for the use of biomedical physics (BMP) educators teaching the non-physics healthcare professions (HCP) in Europe. A comprehensive, qualitative cross-sectional Europe-wide survey of the curricula delivered by BMP in Faculties of Medicine and Health Sciences (FMHS) was carried out. Curricular content was collected from faculty web-sites, curricular documents and textbooks. The survey data was supplemented with semi-structured interviews and direct observation during onsite visits. The number of faculties studied was 118 from 67 universities spread all over Europe, whilst the number of onsite visits/interviews was 15 (geographically distributed as follows: Eastern Europe 6, North Western Europe 5, and South Western Europe 4). EU legislation, recommendations by European national medical councils, educational benchmark statements by higher education quality assurance agencies, research journals concerning HCP education and other documents relevant to standards in clinical practice and undergraduate education were also analyzed. Best practices and BMP learning outcomes were elicited from the curricular materials, interviews and documentation and these were subsequently used to construct the curriculum development model. A structured, comprehensive BMP learning outcomes inventory was designed in the format required by the European Qualifications Framework (EQF). The structures of the inventory and curriculum development model make them ideally suited for use by BMP involved in European curriculum development initiatives for the HCP.
Collapse
Affiliation(s)
- C J Caruana
- Medical Physics, Faculty of Health Sciences, University of Malta, Msida, Malta.
| | | | - V Mornstein
- Department of Biophysics, Medical Faculty, Masaryk University, Brno, Czech Republic
| | - E Vano
- Medical Physics, Radiology Department, School of Medicine, Complutense University, Madrid, Spain
| | - E Pace
- Medical Physics, Medical Imaging Department, Mater Dei University Hospital, Msida, Malta
| | - A A Lammertsma
- Chair of EFOMP Education & Training Committee & Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands
| | - A J J Maas
- Chair of EFOMP Professional Matters Committee & Member MREC Brabant, Tilburg, Netherlands
| | - C Bert
- Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - B Byrne
- Medical Physics, Mater Misericordiae University Hospital, Dublin, Ireland
| | - N Colgan
- School of Physics, National University of Ireland & Medical Physics, Galway University Hospital, Galway, Ireland
| | - M Essers
- Medical Physics and Instrumentation, Institute Verbeeten, Netherlands
| | - J Isidoro
- Medical Physics and Radiation Protection, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - I Koniarova
- National Radiation Protection Institute, Department of Radiation Protection in Radiotherapy, Prague, Czech Republic
| | - A Makridou
- Medical Physics, Thessaloniki Cancer Hospital "Theagenio", Thessaloniki, Greece
| | - C Pesznyak
- Radiotherapy Centre, National Institute of Oncology & Institute of Nuclear Techniques, Budapest University of Technology and Economics, Budapest, Hungary
| | - H S Rønde
- Medical Physics, Danish Centre for Particle Therapy, Aarhus Universitetshospital, Aarhus, Denmark
| | - J Winiecki
- Medical Physics Department, prof. Franciszek Lukaszczyk Memorial Oncology Centre & Collegium Medicum Nicholas Copernicus University, Bydgoszcz, Poland
| |
Collapse
|
4
|
Verwer EE, Golla SSV, Kaalep A, Lubberink M, van Velden FHP, Bettinardi V, Yaqub M, Sera T, Rijnsdorp S, Lammertsma AA, Boellaard R. Harmonisation of PET/CT contrast recovery performance for brain studies. Eur J Nucl Med Mol Imaging 2021; 48:2856-2870. [PMID: 33517517 PMCID: PMC8263427 DOI: 10.1007/s00259-021-05201-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Accepted: 01/10/2021] [Indexed: 12/24/2022]
Abstract
PURPOSE In order to achieve comparability of image quality, harmonisation of PET system performance is imperative. In this study, prototype harmonisation criteria for PET brain studies were developed. METHODS Twelve clinical PET/CT systems (4 GE, 4 Philips, 4 Siemens, including SiPM-based "digital" systems) were used to acquire 30-min PET scans of a Hoffman 3D Brain phantom filled with ~ 33 kBq·mL-1 [18F]FDG. Scan data were reconstructed using various reconstruction settings. The images were rigidly coregistered to a template (voxel size 1.17 × 1.17 × 2.00 mm3) onto which several volumes of interest (VOIs) were defined. Recovery coefficients (RC) and grey matter to white matter ratios (GMWMr) were derived for eroded (denoted in the text by subscript e) and non-eroded grey (GM) and white (WM) matter VOIs as well as a mid-phantom cold spot (VOIcold) and VOIs from the Hammers atlas. In addition, left-right hemisphere differences and voxel-by-voxel differences compared to a reference image were assessed. RESULTS Systematic differences were observed for reconstructions with and without point-spread-function modelling (PSFON and PSFOFF, respectively). Normalising to image-derived activity, upper and lower limits ensuring image comparability were as follows: for PSFON, RCGMe = [0.97-1.01] and GMWMre = [3.51-3.91] for eroded VOI and RCGM = [0.78-0.83] and GMWMr = [1.77-2.06] for non-eroded VOI, and for PSFOFF, RCGMe = [0.92-0.99] and GMWMre = [3.14-3.68] for eroded VOI and RCGM = [0.75-0.81] and GMWMr = [1.72-1.95] for non-eroded VOI. CONCLUSIONS To achieve inter-scanner comparability, we propose selecting reconstruction settings based on RCGMe and GMWMre as specified in "Results". These proposed standards should be tested prospectively to validate and/or refine the harmonisation criteria.
Collapse
Affiliation(s)
- E E Verwer
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| | - S S V Golla
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - A Kaalep
- Department of Medical Technology, North Estonia Medical Centre Foundation, Tallinn, Estonia.,EANM Research Limited (EARL), Vienna, Austria
| | - M Lubberink
- Department of Surgical Sciences / Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden
| | - F H P van Velden
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - V Bettinardi
- IRCCS Scientific Institute San Raffaele Hospital, Milan, Italy
| | - M Yaqub
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - T Sera
- EANM Research Limited (EARL), Vienna, Austria.,Department of Nuclear Medicine, University of Szeged, Szeged, Hungary
| | - S Rijnsdorp
- Department of Medical Physics, Catharina Hospital Eindhoven, Eindhoven, The Netherlands
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - R Boellaard
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| |
Collapse
|
5
|
van de Stadt EA, Yaqub M, Lammertsma AA, Poot AJ, Schober PR, Schuit RC, Smit EF, Bahce I, Hendrikse NH. Quantification of [ 18F]afatinib using PET/CT in NSCLC patients: a feasibility study. EJNMMI Res 2020; 10:97. [PMID: 32804306 PMCID: PMC7431492 DOI: 10.1186/s13550-020-00684-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 07/31/2020] [Indexed: 12/09/2022] Open
Abstract
Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission tomography (PET) may identify those patients that respond to afatinib therapy. Therefore, the aim of this study was to find the optimal tracer kinetic model for quantification of [18F]afatinib uptake in NSCLC tumours. Methods [18F]Afatinib PET scans were performed in 10 NSCLC patients. The first patient was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min dynamic [15O]H2O PET scan (370 MBq) followed by a dynamic [18F]afatinib PET scan (342 ± 24 MBq) of 60 or 90 min. Using the Akaike information criterion (AIC), three pharmacokinetic plasma input models were evaluated with both metabolite-corrected sampler-based input and image-derived (IDIF) input functions in combination with discrete blood samples. Correlation analysis of arterial on-line sampling versus IDIF was performed. In addition, perfusion dependency and simplified measures were assessed. Results Ten patients were included. The injected activity of [18F]afatinib was 341 ± 37 MBq. Fifteen tumours could be identified in the field of view of the scanner. Based on AIC, tumour kinetics were best described using an irreversible two-tissue compartment model and a metabolite-corrected sampler-based input function (Akaike 50%). Correlation of plasma-based input functions with metabolite-corrected IDIF was very strong (r2 = 0.93). The preferred simplified uptake parameter was the tumour-to-blood ratio over the 60- to 90-min time interval (TBR60–90). Tumour uptake of [18F]afatinib was independent of perfusion. Conclusion The preferred pharmacokinetic model for quantifying [18F]afatinib uptake in NSCLC tumours was the 2T3K_vb model. TBR60–90 showed excellent correlation with this model and is the best candidate simplified method. Trial registration https://eudract.ema.europa.eu/ nr 2012-002849-38
Collapse
Affiliation(s)
- E A van de Stadt
- Department of Pulmonology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. .,Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
| | - M Yaqub
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - A A Lammertsma
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - A J Poot
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - P R Schober
- Department of Anesthesiology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - R C Schuit
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - E F Smit
- Department of Pulmonology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.,Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - I Bahce
- Department of Pulmonology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.,Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands
| | - N H Hendrikse
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.,Department of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.,Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| |
Collapse
|
6
|
Verweij NJF, Ter Wee M, De Jongh J, Zwezerijnen GCJ, Yaqub M, Boers M, Voskuyl A, Lammertsma AA, Lems W, Van der Laken CJ. SAT0551 WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4380] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Clinical assessment of arthritis is the cornerstone in the diagnosis and treatment of rheumatoid arthritis (RA). Nevertheless, reliable determination of (sub)clinical arthritis can be difficult, especially in the feet. Advanced imaging techniques may contribute to early diagnosis and therapy monitoring through sensitive detection and (quantitative) monitoring of synovitis. Previously, it has been demonstrated that macrophage imaging using (R)-[11C]PK11195 positron emission tomography (PET) allows for highly sensitive and specific imaging of RA disease activity in the hands.(1,2)Whole body macrophage PET imaging that includes the feet has not yet been evaluated in RA.Objectives:To compare whole body macrophage PET imaging to clinical assessment of arthritis activity in clinically active, early RA patients.Methods:Thirty-five previously untreated RA patients (age 54 ± 12, 51% male) with at least two clinically inflamed joints were included. They underwent a whole body (R)-[11C]PK11195 PET/computed tomography (CT) scan in addition to standard clinical assessment of number of tender and swollen joints (TJC and SJC, respectively). Two readers blinded to clinical assessment (GZ and CvdL) visually scored intensity of uptake in joints on a 0 to 3 scale. A PET positive joint score was defined at ≥ 1. Additionally, (R)-[11C]PK11195 uptake in joints was assessed quantitatively as standardized uptake values (SUV). Visual parameters were compared to clinical parameters using Cohen’s kappa, and quantitative parameters were analyzed using an independent T-test.Results:All patients showed enhanced tracer uptake in one or more joints (Figure 1). A total of 168 joints were visually PET positive, with the following distribution: 16% in the wrists, 14% in the metacarpophalangeal joints, 25% in the proximal interphalangeal joints, 4% in the ankles, 37% in the metatarsophalangeal joints. Positivity in other large joints was rare (4%). The number of discrepant findings between PET and clinical outcome (TJC and/or SJC) varied based on anatomic localization; more joints were clinically active in the hands, and more joints were active on the PET scan in the feet. Consequently, agreement between visual PET positivity and clinical activity was low, with only moderate agreement found in the ankles (κ = 0.46 and 0.41 for SJC and TJC respectively). Quantitative PET data showed a trend towards higher SUV values in joints that were clinically tender and/or swollen, reaching a significant difference in the feet (ankles + MTPs) versus SJC (Figure 2; 0.7 vs 1.0,p< 0.001). However, parts of the clinically non-affected joints also depicted moderately increased SUV values, and vice versa.Figure 1.Visual PET uptake in the left MTP5-joint.Figure 2.(R)-[11C]PK11195 (SUV) in both clinically affected and non-affected feet joints (defined as swollen yes or no).Conclusion:Whole body macrophage PET imaging showed clear uptake of (R)-[11C]PK11195 in several joints of clinically active, early RA patients, especially in MTP-joints. The best correlation between quantitative PET data and clinical assessment of swelling was observed in the feet. In general, however, PET also provided distinct information from clinical assessment, which may provide a means for detecting subclinical synovitis. We are performing longitudinal studies to further assess the value of macrophage PET in RA.References:[1]Elzinga EH, et al. J Nucl Med. 2011; 52(1): 77-80.[2]Gent YY, et al. J Rheumatology. 2014; 41: 2145-52Acknowledgments:We thank ReumaNederland and Pfizer for financial support of this investigator initiated study.Disclosure of Interests:Nicki J.F. Verweij: None declared, Marieke ter Wee: None declared, Jerney de Jongh: None declared, Gerben C.J. Zwezerijnen: None declared, Maqsood Yaqub: None declared, Maarten Boers: None declared, Alexandre Voskuyl: None declared, Adriaan A. Lammertsma: None declared, WIllem Lems Grant/research support from: Pfizer, Consultant of: Lilly, Pfizer, Conny J. van der Laken: None declared
Collapse
|
7
|
Bom MJ, Driessen RS, Van Diemen PA, Everaars H, Schumacher SP, Van Rossum AC, Raijmakers PG, Lammertsma AA, Knuuti J, Ahmadi A, Min JK, Leipsic JA, Narula J, Danad I, Knaapen P. 5962Incremental prognostic value of hybrid PET-CT assessed myocardial blood flow, coronary stenosis severity and adverse plaque characteristics. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Management of patients with suspected coronary artery disease (CAD) can be optimized with prognostic information derived from non-invasive imaging such as positron emission tomography (PET) perfusion imaging and coronary computed tomography angiography (CCTA). The aim of the present study was to determine the incremental prognostic value of combined functional testing using PET perfusion imaging and anatomical testing using CCTA-derived stenosis severity and morphological assessment of CCTA-derived plaque morphology.
Methods
In this retrospective study, 539 patients referred for hybrid [15O]H2O PET – CCTA imaging because of suspected CAD were investigated. PET perfusion imaging was used to determine hyperemic myocardial blood flow (MBF), whereas CCTA images were evaluated for obstructive stenosis and high-risk plaque morphology. Major adverse coronary events (MACE) included all-cause death, non-fatal myocardial infarction (MI), urgent revascularization and late non-urgent revascularization (i.e. not guided by initial diagnostic work-up with non-invasive imaging). Kaplan Meier analysis and Cox proportional hazard regression were used to evaluate the independent prognostic value of PET-derived MBF, CCTA-derived stenosis and CCTA-derived high-risk plaque.
Results
During a mean follow-up of 6.8 [4.8–7.9] years, 79 (14.7%) patients experienced MACE, including 23 (4.3%) deaths, 19 (3.5%) MIs, 8 (1.5%) urgent revascularizations and 29 (5.4%) late non-urgent revascularizations. Annualized event rates for normal vs. abnormal results of PET perfusion imaging, CCTA-derived stenosis and high-risk plaque morphology were 1.2% vs 4.1%, 0.6% vs 4.4%, and 1.7% vs 5.6%, respectively (p<0.001 for all). The combined use of these three imaging parameters resulted in excellent long-term risk prediction, with a MACE-free survival of 97% in patients with no positive imaging findings. In contrast, MACE-free survival was only 69% in patients in whom all imaging findings were positive (figure 1). Multivariate Cox proportional hazard regression demonstrated incremental prognostic value of PET perfusion imaging, CCTA-derived stenosis and CCTA-derived high-risk plaques for the occurrence of MACE (p<0.05 for all)
MACE-free survival stratified by PET-CT
Conclusion
PET-derived myocardial blood flow and CCTA-derived stenosis severity and high-risk plaque morphology are independent long-term predictors of adverse cardiac events and provide incremental prognostic value. Combined functional, anatomical and morphological assessment may allow for improved risk stratification in patients with suspected CAD.
Collapse
Affiliation(s)
- M J Bom
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - R S Driessen
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - P A Van Diemen
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - H Everaars
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - S P Schumacher
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - A C Van Rossum
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - P G Raijmakers
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - A A Lammertsma
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - J Knuuti
- Turku University Hospital, Turku, Finland
| | - A Ahmadi
- Icahn School of Medicine at Mount Sinai Hospital, New York, United States of America
| | - J K Min
- Weill Cornell Medical College, New York, United States of America
| | - J A Leipsic
- University of British Columbia, Vancouver, Canada
| | - J Narula
- Icahn School of Medicine at Mount Sinai Hospital, New York, United States of America
| | - I Danad
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| | - P Knaapen
- Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands (The)
| |
Collapse
|
8
|
Everaars H, Van Diemen PA, Bom MJ, Schumacher SP, Van De Ven PM, Raijmakers PG, Lammertsma AA, Hofman MBM, Van Der Geest RJ, Gotte MJW, Van Rossum AC, Nijveldt R, Danad I, Driessen RS, Knaapen P. P5286Cardiac magnetic resonance for quantification of absolute myocardial blood flow: comparison with [15O]H2O positron emission tomography. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Quantification of absolute myocardial perfusion using positron emission tomography (PET) augments diagnostic performance and aids risk stratification in patients with coronary artery disease (CAD). Similar to PET, cardiac magnetic resonance imaging (CMR) allows for quantification of absolute myocardial blood flow (MBF). To date, quantitative CMR perfusion has not been compared with [15O]H2O PET, which is considered to be the gold standard for quantification of MBF.
Purpose
The purpose of this study was to compare CMR measurements of absolute myocardial perfusion to those obtained using [15O]H2O PET.
Methods
Fifty-one patients with stable CAD underwent [15O]H2O PET followed by CMR within 7 days. Late gadolinium enhancement was used to rule out presence of scar tissue. CMR perfusion imaging was performed using a single bolus dual sequence technique. Myocardial perfusion was quantified for the three main vascular territories at rest and during vasodilator stress.
Results
Pooled CMR estimates of absolute MBF correlated well with PET (r=0.79; p<0.001) and showed good agreement (intraclass correlation coefficient [ICC]=0.78; p<0.001). However, rest and stress MBF correlated weakly (r=0.31; p<0.001 for rest MBF and r=0.35; p<0.001 for stress MBF, figure) and showed poor agreement between PET and CMR (ICC=0.24; p<0.001 for rest MBF and ICC=0.34; p<0.001 for stress MBF). Similarly, CMR derived coronary flow reserve (CFR) correlated weakly (r=0.28; p<0.001) and showed poor agreement with PET derived CFR (ICC=0.23; p<0.001). Nevertheless, for a cut-off value of 2.3 mL/min/g for stress MBF and 2.5 for CFR, CMR and PET were concordant in 116 (79%) vascular territories for stress MBF and 104 (75%) vascular territories for CFR.
Per vessel – CMR vs PET perfusion
Conclusions
Resting MBF, stress MBF and CFR measurements correlated poorly with [15O]H2O PET. Nevertheless, stress MBF and CFR were concordant between CMR and [15O]H2O PET in 79% and 75% of vascular territories, respectively.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- H Everaars
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - P A Van Diemen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - M J Bom
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - S P Schumacher
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - P M Van De Ven
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - P G Raijmakers
- VU University Medical Center, Radiology and Nuclear Medicine, Amsterdam, Netherlands (The)
| | - A A Lammertsma
- VU University Medical Center, Radiology and Nuclear Medicine, Amsterdam, Netherlands (The)
| | - M B M Hofman
- VU University Medical Center, Physics and Medical Technology, Amsterdam, Netherlands (The)
| | - R J Van Der Geest
- Leiden University Medical Center, Radiology, Leiden, Netherlands (The)
| | - M J W Gotte
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - A C Van Rossum
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - R Nijveldt
- Radboud University Medical Centre, Cardiology, Nijmegen, Netherlands (The)
| | - I Danad
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - R S Driessen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| | - P Knaapen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands (The)
| |
Collapse
|
9
|
Bom MJ, Driessen RS, Raijmakers PG, Everaars H, Lammertsma AA, Van Rossum AC, Van Royen N, Knuuti J, Maki M, Danad I, Knaapen P. 3005Diagnostic value of longitudinal flow gradient for the presence of hemodynamically significant coronary artery disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M J Bom
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - R S Driessen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - P G Raijmakers
- VU University Medical Center, Radiology & Nuclear Medicine, Amsterdam, Netherlands
| | - H Everaars
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - A A Lammertsma
- VU University Medical Center, Radiology & Nuclear Medicine, Amsterdam, Netherlands
| | - A C Van Rossum
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - N Van Royen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - J Knuuti
- Turku University Hospital, Turku, Finland
| | - M Maki
- Turku University Hospital, Turku, Finland
| | - I Danad
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - P Knaapen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| |
Collapse
|
10
|
Everaars H, De Waard GA, Driessen RS, Danad I, Raijmakers PG, Lammertsma AA, Van Rossum AC, Knaapen P, Van Royen N. 4172Doppler flow velocity and thermodilution to assess coronary flow reserve: head-to head comparison with [15O]H2O PET imaging. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.4172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H Everaars
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - G A De Waard
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - R S Driessen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - I Danad
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - P G Raijmakers
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - A A Lammertsma
- VU University Medical Center, Nuclear Medicine, Amsterdam, Netherlands
| | - A C Van Rossum
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - P Knaapen
- VU University Medical Center, Cardiology, Amsterdam, Netherlands
| | - N Van Royen
- Radboud University Medical Centre, Cardiology, Nijmegen, Netherlands
| |
Collapse
|
11
|
Driessen RS, Raijmakers PG, Danad I, Stuijfzand WJ, Schumacher SP, Leipsic JA, Min JK, Knuuti J, Lammertsma AA, van Rossum AC, van Royen N, Underwood SR, Knaapen P. Automated SPECT analysis compared with expert visual scoring for the detection of FFR-defined coronary artery disease. Eur J Nucl Med Mol Imaging 2018; 45:1091-1100. [PMID: 29470616 PMCID: PMC5954003 DOI: 10.1007/s00259-018-3951-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 01/16/2018] [Indexed: 01/01/2023]
Abstract
Purpose Traditionally, interpretation of myocardial perfusion imaging (MPI) is based on visual assessment. Computer-based automated analysis might be a simple alternative obviating the need for extensive reading experience. Therefore, the aim of the present study was to compare the diagnostic performance of automated analysis with that of expert visual reading for the detection of obstructive coronary artery disease (CAD). Methods 206 Patients (64% men, age 58.2 ± 8.7 years) with suspected CAD were included prospectively. All patients underwent 99mTc-tetrofosmin single-photon emission computed tomography (SPECT) and invasive coronary angiography with fractional flow reserve (FFR) measurements. Non-corrected (NC) and attenuation-corrected (AC) SPECT images were analyzed both visually as well as automatically by commercially available SPECT software. Automated analysis comprised a segmental summed stress score (SSS), summed difference score (SDS), stress total perfusion deficit (S-TPD), and ischemic total perfusion deficit (I-TPD), representing the extent and severity of hypoperfused myocardium. Subsequently, software was optimized with an institutional normal database and thresholds. Diagnostic performances of automated and visual analysis were compared taking FFR as a reference. Results Sensitivity did not differ significantly between visual reading and most automated scoring parameters, except for SDS, which was significantly higher than visual assessment (p < 0.001). Specificity, however, was significantly higher for visual reading than for any of the automated scores (p < 0.001 for all). Diagnostic accuracy was significantly higher for visual scoring (77.2%) than for all NC images scores (p < 0.05), but not compared with SSS AC and S-TPD AC (69.8% and 71.2%, p = 0.063 and p = 0.134). After optimization of the automated software, diagnostic accuracies were similar for visual (73.8%) and automated analysis. Among the automated parameters, S-TPD AC showed the highest accuracy (73.5%). Conclusion Automated analysis of myocardial perfusion SPECT can be as accurate as visual interpretation by an expert reader in detecting significant CAD defined by FFR. Electronic supplementary material The online version of this article (10.1007/s00259-018-3951-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- R S Driessen
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - P G Raijmakers
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - I Danad
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - W J Stuijfzand
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - S P Schumacher
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - J A Leipsic
- Department of Radiology, St. Paul's Hospital, Vancouver, Canada
| | - J K Min
- Department of Radiology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, USA
| | - J Knuuti
- Turku University Hospital and University of Turku, Turku, Finland
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - A C van Rossum
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - N van Royen
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - S R Underwood
- Department of Nuclear Medicine, Royal Brompton Hospital, London, UK
| | - P Knaapen
- Department of Cardiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| |
Collapse
|
12
|
Makris NE, Boellaard R, Menke CW, Lammertsma AA, Huisman MC. An automatic delineation method for bone marrow absorbed dose estimation in (89)Zr PET/CT studies. EJNMMI Phys 2016; 3:13. [PMID: 27447823 PMCID: PMC4958083 DOI: 10.1186/s40658-016-0149-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Accepted: 06/30/2016] [Indexed: 11/10/2022] Open
Abstract
Background The study aims to develop and validate an automatic delineation method for estimating red bone marrow (RM) activity concentration and absorbed dose in 89Zr positron emission tomography/computed tomography (PET/CT) studies. Five patients with advanced colorectal cancer received 37.1 ± 0.9 MBq [89Zr] cetuximab within 2 h after administration of a therapeutic dose of 500 mg m−2 unlabelled cetuximab. Per patient, five PET/CT scans were acquired on a Gemini TF-64 PET/CT scanner at 1, 24, 48, 96 and 144 h post injection. Low dose CT data were used to manually generate volumes of interest (VOI) in the lumbar vertebrae (LV). In addition, LV VOI were generated automatically using an active contour method in a low dose CT. RM activity was then determined by mapping the low dose CT-derived RM VOI onto the corresponding PET scans. Finally, these activities were used to derive residence times and, subsequently, the self and total RM absorbed doses using OLINDA/EXM 1.1. Results High correlations (r2 > 0.85) between manual and automated VOI methods were obtained for both RM activity concentrations and total absorbed doses. On average, the automatic method provided values that were lower than 5 % compared to the manual method. Conclusions An automated and efficient VOI method, based on an active contour approach, was developed, enabling accurate estimates of RM activity concentrations and total absorbed doses. Electronic supplementary material The online version of this article (doi:10.1186/s40658-016-0149-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- N E Makris
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands. .,Present address: CREATIS, CNRS UMR 5220, INSERM U1206, F-69677, Bron, France.
| | - R Boellaard
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - C W Menke
- Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - M C Huisman
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
13
|
Radchenko V, Engle JW, Roy C, Griswold J, Nortier MF, Birnbaum ER, Brugh M, Mirzadeh S, John KD, Fassbender ME, Zhai C, Franssen GM, Petrik M, Laverman P, Decristoforo C, Samia AM, Véronique DP, Brigitte G, Summer D, Kroess A, Rangger C, Haas H, Laverman P, Gerben F, von Guggenberg E, Decristoforo C, Bolzati C, Salvarese N, Refosco F, Meléndez-Alafort L, Carpanese D, Rosato A, Saviano M, Del Gatto A, Comegna D, Zaccaro L, Billaud E, Ahamed M, Cleeren F, Shahbazali E, Noël T, Hessel V, Verbruggen A, Bormans G, Cleeren F, Lecina J, Koole M, Verbruggen A, Bormans G, Lugatoa B, Stucchia S, Turollaa EA, Giulianoa L, Toddea S, Ferraboschib P, Klok RP, Mooijer MPJ, Hendrikse NH, Windhorst AD, Collet C, Petry N, Chrétien F, Karcher G, Pellegrini-Moïse N, Lamandé-Langle S, Pfaff S, Philippe C, Mitterhauser M, Hacker M, Wadsak W, Guérard F, Lee YS, Gouard S, Baidoo K, Alliot C, Chérel M, Brechbiel MW, Gestin JF, Lam K, Chan C, Reilly RM, Paillas S, Marshall J, Pouget JP, Sosabowski J, Briard E, Auberson YP, Reilly J, Healy M, Sykes D, Paulus A, Lichtenbelt WVM, Mottaghy F, Bauwens M, Baranski AC, Schäfer M, Bauder-Wüst U, Haberkorn U, Eder M, Kopka K, Chaussard M, Hosten B, Vignal N, Tsoupko-Sitnikov V, Hernio N, Hontonnou F, Merlet P, Poyet JL, Sarda-Mantel L, Rizzo-Padoin N, Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Seibert O, Giesel F, Haberkorn U, Eder M, Kopka K, Nematallah M, Michel P, Samia AM, Véronique DP, Roger L, Brigitte G, Fernandez-Maza L, Rivera-Marrero S, Capote AP, Parrado-Gallego A, Fernandez-Gomez I, Balcerzyk M, Sablon-Carrazana M, Perera-Pintado A, Merceron-Martinez D, Acosta-Medina E, Rodriguez-Tanty C, Attili B, Ahamed M, Bormans G, Philippe C, Zeilinger M, Scherer T, Fürnsinn C, Dumanic M, Wadsak W, Hacker M, Mitterhauser M, Janssen B, Vugts DJ, Molenaar GT, Funke U, Kruijer PS, Dollé F, Bormans G, Lammertsma AA, Windhorst AD, Vermeulen K, Ahamed M, Schnekenburger M, Froeyen M, Olberg DE, Diederich M, Bormansa G, Raaphorst RM, Luurtsema G, Lammertsma AA, Elsinga PH, Windhorst AD, Rotteveel L, Funke U, ten Dijke P, Bogaard HJ, Lammertsma AA, Windhorst AD, Song L, Able S, Falzone N, Kersemans V, Vallis K, Carta D, Salvarese N, Sihver W, Gao F, Pietzsch HJ, Biondi B, Ruzza P, Refosco F, Bolzati C, Haubner R, Finkensted A, Stegmair A, Rangger C, Decristoforo C, Zoller H, Virgolini IJ, Pooters I, Lotz M, Wierts R, Mottaghy F, Bauwens M, Forsback S, Jörgen B, Riikka K, Karageorgou M, Radović M, Tsoukalas C, Antic B, Gazouli M, Paravatou-Petsotas M, Xanthopouls S, Calamiotou M, Stamopoulos D, Vranješ-Durić S, Bouziotis P, Lunev AS, Larenkov AA, Petrosova KA, Klementyeva OE, Kodina GE, Kvernenes OH, Adamsen TCH, Martin R, Weidlich S, Zerges AM, Gameiro C, Lazarova N, Müllera M, Luurtsema G, de Vries M, Ghyoot M, van der Woude G, Zijlma R, Dierckx R, Boersma HH, Elsinga PH, Lambrecht FY, Er O, Ince M, Avci CB, Gunduz C, Sarı FA, Ocakoglu K, Er O, Ersoz OA, Lambrecht FY, Ince M, Kayabasi C, Gunduz C, Kniess T, Meister S, Fischer S, Steinbach J, Ashfaq R, Iqbal S, ullah Khan I, Iglesias-Jerez R, Martín-Banderas L, Perera-Pintado A, Borrego-Dorado I, Farinha-Antunes I, Kwizera C, Lacivita E, Lucente E, Niso M, De Giorgio P, Perrone R, Colabufo NA, Elsinga PH, Leopoldo M, Vaulina VV, Fedorova OS, Orlovskaja VV, Chen СL, Li GY, Meng FC, Liu RS, Wang HE, Krasikova RN, Meléndez-Alafort L, Abozeid M, Ferro-Flores G, Negri A, Bello M, Uzunov N, Paiusco M, Esposito J, Rosato A, Meléndez-Alafort L, Bolzati C, Ferro-Flores G, Salvarese N, Carpanese D, Abozeid M, Rosato A, Uzunov N, Palmieri L, Verbrugghen T, Glassner M, Hoogenboom R, Staelens S, Wyffels L, Orlovskaja VV, Kuznetsova OF, Fedorova OS, Maleev VI, Belokon YN, Geolchanyan A, Saghyan AS, Mu L, Schibli R, Ametamey SM, Krasikova RN, Revunov E, Malmquist J, Johnström P, Van Valkenburgh J, Steele D, Halldin C, Schou M, Osati S, Paquette M, Beaudoin S, Ali H, Guerin B, Leyton JV, van Lier JE, Di Iorio V, Iori M, Donati C, Lanzetta V, Capponi PC, Rubagotti S, Dreger T, Kunkel F, Asti M, Zhai C, Rangger C, Summer D, Haas H, Decristoforo C, Kijprayoon S, Ruangma A, Ngokpol S, Tuamputsha S, Filp U, Pees A, Taddei C, Pekošak A, Gee AD, Poot AJ, Windhorst AD, Gunay MS, Ozer AY, Erdogan S, Baysal I, Guilloteau D, Chalon S, Galli F, Artico M, Taurone S, Bianchi E, Weintraub BD, Skudlinski M, Signore A, Lepareur N, Noiret N, Hindré F, Lacœuille F, Benoist E, Garin E, Trejo-Ballado F, Zamora-Romo E, Manrique-Arias JC, Gama-Romero HM, Contreras-Castañon G, Tecuapetla-Chantes RG, Avila-Rodriguez MA, Kvaternik H, Hausberger D, Zink C, Rumpf B, Aigner RM, Kvaternik H, Hausberger D, Rumpf B, Aigner RM, Janković D, Lakić M, Savić A, Ristić S, Nikolić N, Vukadinović A, Sabo TJ, Vranješ-Đurić S, Vranješ-Đurić S, Radović M, Janković D, Nikolić N, Goya GF, Calatayud P, Spasojević V, Antić B, Goblet D, Gameiro C, Lazarova N, Gameiro C, Oxley I, Abrunhosa A, Kramer V, Vosjan M, Spaans A, Vats K, Satpati D, Sarma HD, Banerjee S, Wojdowska W, Pawlak DW, Parus LJ, Garnuszek P, Mikołajczak R, Pijarowska-Kruszyna J, Jaron A, Kachniarz A, Malkowski B, Garnuszek P, Mikolajczak R, Ilem-Ozdemir D, Caglayan-Orumlu O, Asikoglu M, Ilem-Ozdemir D, Caglayan-Orumlu O, Asikoglu M, Eveliina A, Semi H, Timo S, Simo V, Esa K, Pertti L, De Simone M, Pascali G, Carzoli L, Quaglierini M, Telleschi M, Salvadori PA, Lam P, Aistleitner M, Eichinger R, Artner C, Nakka S, MC HK, Al-Qahtani M, Al-Qahtani M, Al-Malki Y, Mambilima N, Rubow SM, Berroterán-Infante N, Hacker M, Mitterhauser M, Wadsak W, Funke U, Cleeren F, Lecina J, Gallardo R, Verbruggen AM, Bormans G, Ramos-Membrive R, Brotons A, Quincoces G, Inchaurraga L, de Redín IL, Morán V, García-García B, Irache JM, Peñuelas I, Trabelsi M, Cooper MS, Abella A, Fuente T, Montellano AJ, Martínez T, Rabadan R, Meseguer-Olmo L, Lehtiniemi P, Yim C, Mikkola K, Nuutila P, Solin O, von Guggenberg E, Rangger C, Mair C, Balogh L, Pöstényi Z, Pawlak D, Mikołajczak R, Socan A, Peitl PK, Krošelj M, Rangger C, Decristoforo C, Collet C, Remy S, Didier R, Vergote T, Karcher G, Véran N, Pawlak D, Maurin M, Garnuszek P, Karczmarczyk U, Mikołajczak R, Fredericia P, Severin G, Groesser T, Köster U, Jensen M, Leonte R, Puicea FD, Raicu A, Min EA, Serban R, Manda G, Niculae D, Zerna M, Schieferstein H, Müller A, Berndt M, Yim CB, Mikkola K, Nuutila P, Solin O, Seifert D, Ráliš J, Lebeda O, Selivanova SV, Senta H, Lavallée É, Caouette L, Turcotte É, Lecomte R, Kochovska MZ, Ivanovska EJ, Jokic VS, Ackova DG, Smilkov K, Makreski P, Stafilov T, Janevik-Ivanovska E, Alemu A, Muchira JM, Wanjeh DM, Janevik-Ivanovska E, Janevik-Ivanovska E, Zdravev Z, Bhonsle U, Alberto OJJ, Duatti A, Angelovska B, Stojanovska Z, Sarafinovska ZA, Bosnakovski D, Gorgieva-Ackova D, Smilkov K, Drakalska E, Venkatesh M, Gulaboski R, Colin DJ, Inkster JAH, Germain S, Seimbille Y. 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. EJNMMI Radiopharm Chem 2016. [PMCID: PMC5843810 DOI: 10.1186/s41181-016-0012-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets V. Radchenko, J.W. Engle, C. Roy, J. Griswold, M.F. Nortier, E.R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M.E. Fassbender OP04 Comparison of [68Ga]FSC(succ-RGD)3 and [68Ga]NODAGA-RGD for PET imaging of αvβ3 integrin expression Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo OP05 A new NPY-Y1R targeting peptide for breast cancer PET imaging Ait-Mohand Samia, Dumulon-Perreault Véronique, Guérin Brigitte OP06 The influence of multivalency on CCK 2 receptor targeting D. Summer, A. Kroess, C. Rangger, H. Haas, P. Laverman, F. Gerben, E. von Guggenberg, C.Decristoforo OP07 SPECT Imaging of αvβ3 Expression by [99mTc(N)PNP43]- Bifunctional Chimeric RGD Peptide not Cross-Reacting with αvβ5 Cristina Bolzati, Nicola Salvarese, Fiorenzo Refosco, Laura Meléndez-Alafort, Debora Carpanese, Antonio Rosato, Michele Saviano, Annarita Del Gatto, Daniela Comegna, Laura Zaccaro OP09 New dienophiles for the inverse-electron-demand Diels-Alder reaction and for pretargeted PET imaging Emilie Billaud, Muneer Ahamed, Frederik Cleeren, Elnaz Shahbazali, Tim Noël, Volker Hessel, Alfons Verbruggen and Guy Bormans OP10 New complexing agent for Al18F-labelling of heat-sensitive biomolecules: Synthesis and preclinical evaluation of Al18F-RESCA1-HAS Cleeren F, Lecina J, Koole M, Verbruggen A and Bormans G OP11 A novel versatile precursor efficient for F-18 radiolabelling via click-chemistry B. Lugatoa, S. Stucchia, E.A. Turollaa, L. Giulianoa, S.Toddea, P. Ferraboschib OP12 A general applicable method to quantify unidentified UV impurities in radiopharmaceuticals R.P. Klok, M.P.J. Mooijer, N.H. Hendrikse, A.D. Windhorst OP13 Development of [18F]Fluoro-C-glycosides to radiolabel peptides Collet C., Petry N., Chrétien F., Karcher G., Pellegrini-Moïse N., Lamandé-Langle S. OP14 A Microfluidic Approach for the 68Ga-labeling of PSMAHBED-CC and NODAGA-RGD Sarah Pfaff, Cecile Philippe, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak OP16 Surprising reactivity of astatine in the nucleophilic substitution of aryliodonium salts: application to the radiolabeling of antibodies François Guérard, Yong-Sok Lee, Sébastien Gouard, Kwamena Baidoo, Cyrille Alliot, Michel Chérel, Martin W. Brechbiel, Jean-François Gestin OP17 64Cu-NOTA-pertuzumab F(ab')2 fragments, a second-generation probe for PET imaging of the response of HER2-positive breast cancer to trastuzumab (Herceptin) Lam K, Chan C, Reilly RM OP18 Development of radiohalogenated analogues of a avb6-specific peptide for high LET particle emitter targeted radionuclide therapy of cancer Salomé Paillas, John Marshall, Jean-Pierre Pouget, Jane Sosabowski OP19 Ligand Specific Efficiency (LSE) as a guide in tracer optimization Emmanuelle Briard, Yves P. Auberson, John Reilly, Mark Healy, David Sykes OP23 The radiosynthesis of an 18F-labeled triglyceride, developed to visualize and quantify brown adipose tissue activity Andreas Paulus, Wouter van Marken Lichtenbelt,Felix Mottaghy, Matthias Bauwens OP24 Influence of the fluorescent dye on the tumor targeting properties of dual-labeled HBED-CC based PSMA inhibitors Baranski, Ann-Christin, Schäfer, Martin, Bauder-Wüst, Ulrike, Haberkorn, Uwe, Eder, Matthias, Kopka, Klaus OP25 [18F]MEL050 as a melanin PET tracer : fully automated radiosynthesis and evaluation for the detection of pigmented melanoma in mice pulmonary metastases Chaussard M, Hosten B, Vignal N, Tsoupko-Sitnikov V, Hernio N, Hontonnou F, Merlet P, Poyet JL, Sarda-Mantel L, Rizzo-Padoin N OP26 Design and Preclinical Evaluation of Novel Radiofluorinated PSMA Targeting Ligands Based on PSMA-617 J. Cardinale, M. Schäfer, M. Benešová, U. Bauder-Wüst, O. Seibert, F. Giesel, U. Haberkorn, M. Eder, K. Kopka OP27 A novel radiolabeled peptide for PET imaging of prostate cancer: 64Cu-DOTHA2-PEG-RM26 Mansour Nematallah, Paquette Michel, Ait-Mohand Samia, Dumulon-Perreault Véronique, Lecomte Roger, Guérin Brigitte OP29 Biodistribution of [18F]Amylovis®, a new radiotracer PET imaging of β-amyloid plaques Fernandez-Maza L, Rivera-Marrero S, Prats Capote A, Parrado-Gallego A, Fernandez-Gomez I, Balcerzyk M, Sablon-Carrazana M, Perera-Pintado A, Merceron-Martinez D, Acosta-Medina E, Rodriguez-Tanty C OP30 Synthesis and preclinical evaluation of [11C]-BA1 PET tracer for the imaging of CSF-1R Bala Attili, Muneer Ahamed, Guy Bormans OP31 In vivo imaging of the MCHR1 in the ventricular system via [18F]FE@SNAP C. Philippe, M. Zeilinger, T. Scherer, C. Fürnsinn, M. Dumanic, W. Wadsak, M. Hacker, M. Mitterhauser OP32 Synthesis of the first carbon-11 labelled P2Y12 receptor antagonist for imaging the anti-inflammatory phenotype of activated microglia B. Janssen, D.J. Vugts, G.T. Molenaar, U. Funke, P.S. Kruijer, F. Dollé, G. Bormans, A.A. Lammertsma, A.D. Windhorst OP33 Radiosynthesis of a selective HDAC6 inhibitor [11C]KB631 and in vitro and ex vivo evaluation Koen Vermeulen, Muneer Ahamed, Michael Schnekenburger, Mathy Froeyen, Dag Erlend Olberg, Marc Diederich, Guy Bormansa OP34 Improving metabolic stability of fluorine-18 labelled verapamil analogues Raaphorst RM, Luurtsema G, Lammertsma AA, Elsinga PH, Windhorst AD OP36 Development of a novel PET tracer for the activin receptor-like kinase 5 Lonneke Rotteveel, Uta Funke, Peter ten Dijke, Harm Jan Bogaard, Adriaan A. Lammertsma, Albert D. Windhorst OP37 SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo Lei Song, Sarah Able, Nadia Falzone, Veerle Kersemans, Katherine Vallis OP38 Melanoma targeting with [99mTc(N)(PNP3)]-labeled NAPamide derivatives: preliminary pharmacological studies Davide Carta, Nicola Salvarese, Wiebke Sihver, Feng Gao, Hans Jürgen Pietzsch, Barbara Biondi, Paolo Ruzza, Fiorenzo Refosco, Cristina Bolzati OP39 [68Ga]NODAGA-RGD: cGMP synthesis and data from a phase I clinical study Roland Haubner, Armin Finkensted, Armin Stegmair, Christine Rangger, Clemens Decristoforo, Heinz Zoller, Irene J. Virgolin OP44 Implementation of a GMP-grade radiopharmacy facility in Maastricht Ivo Pooters, Maartje Lotz, Roel Wierts, Felix Mottaghy, Matthias Bauwens OP45 Setting up a GMP production of a new radiopharmaceutical Forsback, Sarita, Bergman Jörgen, Kivelä Riikka OP48 In vitro and in vivo evaluation of 68-gallium labeled Fe3O4-DPD nanoparticles as potential PET/MRI imaging agents M. Karageorgou, M. Radović, C. Tsoukalas, B. Antic, M. Gazouli, M. Paravatou-Petsotas, S. Xanthopouls, M. Calamiotou, D. Stamopoulos, S. Vranješ-Durić, P. Bouziotis OP49 Fast PET imaging of inflammation using 68Ga-citrate with Fe-containing salts of hydroxy acids A. S. Lunev, A. A. Larenkov, K.A. Petrosova, O. E. Klementyeva, G. E. Kodina PP01 Installation and validation of 11C-methionine synthesis Kvernenes, O.H., Adamsen, T.C.H. PP02 Fully automated synthesis of 68Ga-labelled peptides using the IBA Synthera® and Synthera® Extension modules René Martin, Sebastian Weidlich, Anna-Maria Zerges, Cristiana Gameiro, Neva Lazarova, Marco Müllera PP03 GMP compliant production of 15O-labeled water using IBA 18 MeV proton cyclotron Gert Luurtsema, Michèl de Vries, Michel Ghyoot, Gina van der Woude, Rolf Zijlma, Rudi Dierckx, Hendrikus H. Boersma, Philip H. Elsinga PP04 In vitro Nuclear Imaging Potential of New Subphthalocyanine and Zinc Phthalocyanine Fatma Yurt Lambrecht, Ozge Er, Mine Ince, Cıgır Biray Avci, Cumhur Gunduz, Fatma Aslihan Sarı PP05 Synthesis, Photodynamic Therapy Efficacy and Nuclear Imaging Potential of Zinc Phthalocyanines Kasim Ocakoglu, Ozge Er, Onur Alp Ersoz, Fatma Yurt Lambrecht, Mine Ince, Cagla Kayabasi, Cumhur Gunduz PP06 Radio-U(H)PLC – the Search on the Optimal Flow Cell for the γ-Detector Torsten Kniess, Sebastian Meister, Steffen Fischer, Jörg Steinbach PP07 Radiolabeling, characterization & biodistribution study of cysteine and its derivatives with Tc99m Rabia Ashfaq, Saeed Iqbal, Atiq-ur-Rehman, Irfan ullah Khan PP08 Radiolabelling of poly (lactic-co.glycolic acid) (PLGA) nanoparticles with 99mTC R Iglesias-Jerez, Cayero-Otero, L. Martín-Banderas, A. Perera-Pintado, I. Borrego-Dorado PP09 Development of [18F]PD-410 as a non-peptidic PET radiotracer for gastrin releasing peptide receptors Ines Farinha-Antunes, Chantal Kwizera, Enza Lacivita, Ermelinda Lucente, Mauro Niso, Paola De Giorgio, Roberto Perrone, Nicola A. Colabufo, Philip H. Elsinga, Marcello Leopoldo PP10 An improved nucleophilic synthesis of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy) benzothiazole ([18F]FEDMBT), potential diagnostic agent for breast cancer imaging by PET V.V. Vaulina, O.S. Fedorova, V.V. Orlovskaja, С.L. Chen, G.Y. Li, F.C. Meng, R.S. Liu, H.E. Wang, R.N. Krasikova PP11 Internal radiation dose assessment of radiopharmaceuticals prepared with accelerator-produced 99mTc Laura Meléndez-Alafort, Mohamed Abozeid, Guillermina Ferro-Flores, Anna Negri, Michele Bello, Nikolay Uzunov, Martha Paiusco, Juan Esposito, Antonio Rosato PP12 A specialized five-compartmental model software for pharmacokinetic parameters calculation Laura Meléndez-Alafort, Cristina Bolzati, Guillermina Ferro-Flores, Nicola Salvarese, Debora Carpanese, Mohamed Abozeid, Antonio Rosato, Nikolay Uzunov PP13 Molecular imaging of the pharmacokinetic behavior of low molecular weight 18F-labeled PEtOx in comparison to 89Zr-labeled PEtOx Palmieri L, Verbrugghen T, Glassner M, Hoogenboom R, Staelens S, Wyffels L PP14 Towards nucleophilic synthesis of the α-[18F]fluoropropyl-L-dihydroxyphenylalanine V. V. Orlovskaja, O. F. Kuznetsova, O. S. Fedorova, V. I. Maleev, Yu. N. Belokon, A. Geolchanyan, A. S. Saghyan, L. Mu, R. Schibli, S. M. Ametamey, R. N. Krasikova PP15 A convenient one-pot synthesis of [18F]clofarabine Revunov, Evgeny, Malmquist, Jonas, Johnström, Peter, Van Valkenburgh, Juno, Steele, Dalton, Halldin, Christer, Schou, Magnus PP16 BODIPY-estradiol conjugates as multi-modality tumor imaging agents Samira Osati,Michel Paquette,Simon Beaudoin,Hasrat Ali,Brigitte Guerin, Jeffrey V. Leyton, Johan E. van Lier PP17 Easy and high yielding synthesis of 68Ga-labelled HBED-PSMA and DOTA-PSMA by using a Modular-Lab Eazy automatic synthesizer Di Iorio V, Iori M, Donati C, Lanzetta V, Capponi PC, Rubagotti S, Dreger T, Kunkel F, Asti M PP18 Synthesis and evaluation of fusarinine C-based octadentate bifunctional chelators for zirconium-89 labelling Chuangyan Zhai, Christine Rangger, Dominik Summer, Hubertus Haas, Clemens Decristoforo PP19 Fully automated production of [18F]NaF using a re-configuring FDG synthesis module. Suphansa Kijprayoon, Ananya Ruangma, Suthatip Ngokpol, Samart Tuamputsha PP20 Extension of the Carbon-11 Small Labeling Agents Toolbox and Conjugate Addition Ulrike Filp, Anna Pees, Carlotta Taddei, Aleksandra Pekošak, Antony D. Gee, Alex J. Poot, Albert D. Windhorst PP21 In vitro studies on BBB penetration of pramipexole encapsulated theranostic liposomes for the therapy of Parkinson’s disease Mine Silindir Gunay, A. Yekta Ozer, Suna Erdogan, Ipek Baysal, Denis Guilloteau, Sylvie Chalon PP22 Factors affecting tumor uptake of 99mTc-HYNIC-VEGF165 Filippo Galli, Marco Artico, Samanta Taurone, Enrica Bianchi, Bruce D. Weintraub, Mariusz Skudlinski, Alberto Signore PP23 Rhenium-188: a suitable radioisotope for targeted radiotherapy Nicolas Lepareur, Nicolas Noiret, François Hindré, Franck Lacœuille, Eric Benoist, Etienne Garin PP24 Preparation of a broad palette of 68Ga radiopharmaceuticals for clinical applications Trejo-Ballado F, Zamora-Romo E, Manrique-Arias JC, Gama-Romero HM, Contreras-Castañon G, Tecuapetla-Chantes RG, Avila-Rodriguez MA PP25 68Ga-peptide preparation with the use of two 68Ge/68Ga-generators H. Kvaternik, D. Hausberger, C. Zink, B. Rumpf, R. M. Aigner PP26 Assay of HEPES in 68Ga-peptides by HPLC H. Kvaternik, D. Hausberger, B. Rumpf, R. M. Aigner PP27 Preparation, in vitro and in vivo evaluation of a 99mTc(I)-Diethyl Ester (S,S)-Ethylenediamine- N,N´-DI-2-(3-Cyclohexyl) Propionic acid as a target-specific radiopharmaceutical Drina Janković, Mladen Lakić, Aleksandar Savić, Slavica Ristić, Nadežda Nikolić, Aleksandar Vukadinović, Tibor J. Sabo, Sanja Vranješ-Đurić PP28 90Y-labeled magnetite nanoparticles for possible application in cancer therapy S. Vranješ-Đurić, M. Radović, D. Janković, N. Nikolić, G. F. Goya, P. Calatayud, V. Spasojević, B. Antić PP29 Simplified automation of the GMP production of 68Ga-labelled peptides David Goblet, Cristiana Gameiro, Neva Lazarova PP30 Combining commercial production of multi-products in a GMP environment with Clinical & R&D activities Cristiana Gameiro, Ian Oxley, Antero Abrunhosa, Vasko Kramer, Maria Vosjan, Arnold Spaans PP31 99mTc(CO)3-labeling and Comparative In-Vivo Evaluation of Two Clicked cRGDfK Peptide Derivatives Kusum Vats, Drishty Satpati, Haladhar D Sarma, Sharmila Banerjee PP32 Application of AnaLig resin for 99mTc separation from molybdenum excess Wojdowska W., Pawlak D.W., Parus L. J., Garnuszek P., Mikołajczak R. PP33 Constraints for selection of suitable precursor for one-step automated synthesis of [18F]FECNT, the dopamine transporter ligand Pijarowska-Kruszyna J, Jaron A, Kachniarz A, Malkowski B, Garnuszek P, Mikolajczak R PP34 Gamma scintigraphy studies with 99mTc- amoxicillin sodium in bacterially infected and sterile inflamed rats Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu PP35 Preparation of 99mTc- Amoxicillin Sodium Lyophilized Kit Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu PP36 Outfits of Tracerlan FXC-PRO for 11C-Labeling Arponen Eveliina, Helin Semi, Saarinen Timo, Vauhkala Simo, Kokkomäki Esa, Lehikoinen Pertti PP37 Microfluidic synthesis of ω-[18F]fluoro-1-alkynes Mariarosaria De Simone, Giancarlo Pascali, Ludovica Carzoli, Mauro Quaglierini, Mauro Telleschi, Piero A. Salvadori PP38 Automated 18F-flumazenil production using chemically resistant disposable cassettes Phoebe Lam, Martina Aistleitner, Reinhard Eichinger, Christoph Artner PP39 The effect of the eluent solutions (TBAHCO3, Kryptand K2.2.2) on the radiochemical yields of 18F-Fluoromethylcholine Surendra Nakka, Hemantha Kumara MC, Al-Qahtani Mohammed PP40 [68Ga]Radiolabeling of short peptide that has a PET imaging potentials Al-Qahtani, Mohammed, Al-Malki, Yousif PP41 Is validation of radiochemical purity analysis in a public hospital in a developing country possible? N Mambilima, SM Rubow PP42 Improved automated radiosynthesis of [18F]FEPPA N. Berroterán-Infante, M. Hacker, M. Mitterhauser, W. Wadsak PP43 Synthesis and initial evaluation of Al18F-RESCA1-TATE for somatostatin receptor imaging with PET Uta Funke, Frederik Cleeren, Joan Lecina, Rodrigo Gallardo, Alfons M. Verbruggen, Guy Bormans PP44 Radiolabeling and SPECT/CT imaging of different polymer-decorated zein nanoparticles for oral administration Rocío Ramos-Membrive, Ana Brotons, Gemma Quincoces, Laura Inchaurraga, Inés Luis de Redín, Verónica Morán, Berta García-García, Juan Manuel Irache, Iván Peñuelas PP45 An analysis of the quality of 68Ga-DOTANOC radiolabelling over a 3 year period Trabelsi, M., Cooper M.S. PP46 In vivo biodistribution of adult human mesenchymal stem cells I (MSCS-ah) labeled with 99MTC-HMPAO administered via intravenous and intra-articular in animal model. Preliminary results Alejandra Abella, Teodomiro Fuente, Antonio Jesús Montellano, Teresa Martínez, Ruben Rabadan, Luis Meseguer-Olmo PP47 Synthesis of [18F]F-exendin-4 with high specific activity Lehtiniemi P, Yim C, Mikkola K, Nuutila P, Solin O PP48 Experimental radionuclide therapy with 177Lu-labelled cyclic minigastrin and human dosimetry estimations von Guggenberg E, Rangger C, Mair C, Balogh L, Pöstényi Z, Pawlak D, Mikołajczak R PP49 Synthesis of radiopharmaceuticals for cell radiolabelling using anion exchange column Socan A, Kolenc Peitl P, Krošelj M, Rangger C, Decristoforo C PP50 [68Ga]peptide production on commercial synthesiser mAIO Collet C., Remy S., Didier R,Vergote T.,Karcher G., Véran N. PP51 Dry kit formulation for efficient radiolabeling of 68Ga-PSMA D. Pawlak, M. Maurin, P. Garnuszek, U. Karczmarczyk, R. Mikołajczak PP52 Development of an experimental method using Cs-131 to evaluate radiobiological effects of internalized Auger-electron emitters Pil Fredericia, Gregory Severin, Torsten Groesser, Ulli Köster, Mikael Jensen PP53 Preclinical comparative evaluation of NOTA/NODAGA/DOTA CYCLO-RGD peptides labelled with Ga-68 R. Leonte, F. D. Puicea, A. Raicu, E. A. Min, R. Serban, G. Manda, D. Niculae PP54 Synthesizer- and Kit-based preparation of prostate cancer imaging agent 68Ga-RM2 Marion Zerna, Hanno Schieferstein, Andre Müller, Mathias Berndt PP55 Synthesis of pancreatic beta cell-specific [18F]fluoro-exendin-4 via strain-promoted aza-dibenzocyclooctyne/azide cycloaddition Cheng-Bin Yim, Kirsi Mikkola, Pirjo Nuutila, Olof Solin PP56 Automated systems for radiopharmacy D. Seifert, J. Ráliš, O. Lebeda PP57 Simple, suitable for everyday routine use quality control method to assess radionuclidic purity of cyclotron-produced 99mTc Svetlana V. Selivanova, Helena Senta, Éric Lavallée, Lyne Caouette, Éric Turcotte, Roger Lecomte PP58 Effective dose estimation using Monte Carlo simulation for patients undergoing radioiodine therapy Marina Zdraveska Kochovska, Emilija Janjevik Ivanovska, Vesna Spasic Jokic PP59 Chemical analysis of the rituximab radioimmunoconjugates in lyophilized formulations intended for oncological applications Darinka Gjorgieva Ackova, Katarina Smilkov, Petre Makreski, Trajče Stafilov, Emilija Janevik-Ivanovska PP61 The need and benefits of established radiopharmacy in developing African countries Aschalew Alemu, Joel Munene Muchira, David Mwanza Wanjeh, Emilija Janevik-Ivanovska PP62 University Master Program of Radiopharmacy – step forward for Good Radiopharmacy Education Emilija Janevik-Ivanovska, Zoran Zdravev, Uday Bhonsle, Osso Júnior João Alberto, Adriano Duatti, Bistra Angelovska, Zdenka Stojanovska, Zorica Arsova Sarafinovska, Darko Bosnakovski, Darinka Gorgieva-Ackova, Katarina Smilkov, Elena Drakalska, Meera Venkatesh, Rubin Gulaboski PP63 Synthesis and preclinical validations of a novel 18F-labelled RGD peptide prepared by ligation of a 2-cyanobenzothiazole with 1,2-aminothiol to image angiogenesis. Didier J. Colin, James A. H. Inkster, Stéphane Germain, Yann Seimbille
Collapse
|
14
|
Heijtel DFR, Petersen ET, Mutsaerts HJMM, Bakker E, Schober P, Stevens MF, van Berckel BNM, Majoie CBLM, Booij J, van Osch MJP, van Bavel ET, Boellaard R, Lammertsma AA, Nederveen AJ. Quantitative agreement between [(15)O]H2O PET and model free QUASAR MRI-derived cerebral blood flow and arterial blood volume. NMR Biomed 2016; 29:519-526. [PMID: 26876426 DOI: 10.1002/nbm.3480] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 11/13/2015] [Accepted: 12/08/2015] [Indexed: 06/05/2023]
Abstract
The purpose of this study was to assess whether there was an agreement between quantitative cerebral blood flow (CBF) and arterial cerebral blood volume (CBVA) measurements by [(15)O]H2O positron emission tomography (PET) and model-free QUASAR MRI. Twelve healthy subjects were scanned within a week in separate MRI and PET imaging sessions, after which quantitative and qualitative agreement between both modalities was assessed for gray matter, white matter and whole brain region of interests (ROI). The correlation between CBF measurements obtained with both modalities was moderate to high (r(2): 0.28-0.60, P < 0.05), although QUASAR significantly underestimated CBF by 30% (P < 0.001). CBVA was moderately correlated (r(2): 0.28-0.43, P < 0.05), with QUASAR yielding values that were only 27% of the [(15)O]H2O-derived values (P < 0.001). Group-wise voxel statistics identified minor areas with significant contrast differences between [(15)O]H2O PET and QUASAR MRI, indicating similar qualitative CBVA and CBF information by both modalities. In conclusion, the results of this study demonstrate that QUASAR MRI and [(15)O]H2O PET provide similar CBF and CBVA information, but with systematic quantitative discrepancies.
Collapse
Affiliation(s)
- D F R Heijtel
- Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands
| | - E T Petersen
- Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - H J M M Mutsaerts
- Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands
| | - E Bakker
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - P Schober
- Department of Anesthesiology, VU University Medical Center, Amsterdam, the Netherlands
| | - M F Stevens
- Department of Anesthesiology, Academic Medical Center, Amsterdam, the Netherlands
| | - B N M van Berckel
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - C B L M Majoie
- Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands
| | - J Booij
- Department of Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands
| | - M J P van Osch
- C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - E T van Bavel
- Department of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, the Netherlands
| | - R Boellaard
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - A J Nederveen
- Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
15
|
Romijn MA, Danad I, Bakkum MJ, Stuijfzand WJ, Tulevski II, Somsen GA, Lammertsma AA, van Kuijk C, van de Ven PM, Min JK, Leipsic J, van Rossum AC, Raijmakers PG, Knaapen P. Incremental diagnostic value of epicardial adipose tissue for the detection of functionally relevant coronary artery disease. Atherosclerosis 2015; 242:161-6. [PMID: 26188540 DOI: 10.1016/j.atherosclerosis.2015.07.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 06/09/2015] [Accepted: 07/02/2015] [Indexed: 01/03/2023]
Abstract
BACKGROUND AND AIM To determine the incremental diagnostic value of epicardial adipose tissue (EAT) volume in addition to the coronary artery calcium (CAC) score for detecting hemodynamic significant coronary artery disease (CAD). METHODS AND RESULTS 122 patients (mean age 61 ± 10 years, 61% male) without a previous cardiac history underwent a non-contrast CT scan for calcium scoring and EAT volume measurements. Subsequently all patients underwent invasive coronary angiography (ICA) in conjunction with fractional flow reserve (FFR) measurements. A stenosis >90% and/or a FFR ≤0.80 were considered significant. Mean EAT volume and CACscore were 128 ± 51 cm(3) and 418 ± 704, respectively. The correlation between EAT volume and the CACscore was poor (r = 0.11, p = 0.24). Male gender (odds ratio [OR] 2.86, p = 0.01), CACscore ([cut-off value 100] OR 3.31, p = 0.003, and EAT volume ([cut-off value 92 cm(3)] OR 4.28, p = 0.01) were associated with flow-limiting disease. The multivariate model revealed that only male gender (OR 2.50, p = 0.045), CAC score (OR 3.60, p = 0.005), and EAT volume (OR 4.95, p = 0.02) were independent predictors of myocardial ischemia. Using the cut-off values of 100 (CAC score) and 92 cm(3) (EAT volume), sensitivity, specificity, negative predictive value, positive predictive value, and accuracy for detecting functionally relevant CAD as indicated by FFR were 71, 57, 77, 50 and 63% and 91, 29, 85, 44 and 52% for the CACscore and EAT volume, respectively. Adding EAT volume to the CAC score and cardiovascular risk factors did not enhance diagnostic performance for the detection of significant CAD (p = 0.57). CONCLUSION EAT volume measurements have no diagnostic value beyond calcium scoring and cardiovascular risk factors in the detection of hemodynamic significant CAD.
Collapse
Affiliation(s)
- M A Romijn
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands
| | - I Danad
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands.
| | - M J Bakkum
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands
| | - W J Stuijfzand
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands
| | - I I Tulevski
- Cardiology Centers of the Netherlands, Amsterdam, The Netherlands
| | - G A Somsen
- Cardiology Centers of the Netherlands, Amsterdam, The Netherlands
| | - A A Lammertsma
- VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
| | - C van Kuijk
- VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
| | - P M van de Ven
- VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam, The Netherlands
| | - J K Min
- Dalio Institute of Cardiovascular Imaging, Weill Cornell Medical College and The NewYork-Presbyterian Hospital, New York, NY, United States
| | - J Leipsic
- Department of Medical Imaging and Division of Cardiology, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| | - A C van Rossum
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands
| | - P G Raijmakers
- VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
| | - P Knaapen
- VU University Medical Center, Department of Cardiology, Amsterdam, The Netherlands
| |
Collapse
|
16
|
Makris NE, van Velden FHP, Huisman MC, Menke CW, Lammertsma AA, Boellaard R. Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses. Med Phys 2015; 41:102503. [PMID: 25281978 DOI: 10.1118/1.4895973] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
PURPOSE Increasing interest in immuno-positron emission tomography (PET) studies requires development of dosimetry methods which will provide accurate estimations of organ absorbed doses. The purpose of this study is to develop and validate simplified dosimetry approaches for (89)Zirconium-PET (Zr-PET)/computed tomography (CT) studies. METHODS Five patients with advanced colorectal cancer received 37.1 ± 0.9 MBq (89)Zr-cetuximab within 2 h after administration of a therapeutic dose of 500 mg m(-2) cetuximab. PET/CT scans were obtained 1, 24, 48, 94, and 144 h post injection. Volumes of interest (VOIs) were manually delineated in lungs, liver, spleen, and kidneys for all scans, providing a reference VOI set. Simplified manual VOIs were drawn independently on CT scans using larger voxel sizes. The transformation of VOIs based on rigid and/or nonrigid registrations of the first CT scan (CT1) onto all successive CT scans was also investigated. The transformation matrix obtained from each registration was applied to the manual VOIs of CT₁ to obtain VOIs for the successive scans. Dice similarity coefficient (DSC) and Hausdorff distance were used to assess the performance of the registrations. Organ total activity, organ absorbed dose, and effective dose were calculated for all methods. RESULTS Semi-automatic delineation based on nonrigid registration showed excellent agreement for lungs and liver (DSC: 0.90 ± 0.04; 0.81 ± 0.06) and good agreement for spleen and kidneys (DSC: 0.71 ± 0.07; 0.66 ± 0.08). Hausdorff distance ranged from 13 to 16 mm depending on the organ. Simplified manual delineation methods, in liver and lungs, performed similarly to semi-automatic delineation methods. For kidneys and spleen, however, poorer accuracy in total activity and absorbed dose was observed, as the voxel size increased. Organ absorbed dose and total activity based on nonrigid registration were within 10%. The effective dose was within ±3% for all VOI delineation methods. CONCLUSIONS A fast, semi-automatic, and accurate delineation method based on nonrigid registration was developed for determination of organ absorbed and effective dose in (89)Zr-PET/CT studies which may also be applied to other long-lived radionuclide PET/CT studies.
Collapse
Affiliation(s)
- N E Makris
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| | - F H P van Velden
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| | - M C Huisman
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| | - C W Menke
- Department of Medical Oncology, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| | - A A Lammertsma
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| | - R Boellaard
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam 1081HZ, The Netherlands
| |
Collapse
|
17
|
Bakkum MJ, Danad I, Romijn MAJ, Stuijfzand WJA, Leonora RM, Tulevski II, Somsen GA, Lammertsma AA, van Kuijk C, van Rossum AC, Raijmakers PG, Knaapen P. The impact of obesity on the relationship between epicardial adipose tissue, left ventricular mass and coronary microvascular function. Eur J Nucl Med Mol Imaging 2015; 42:1562-73. [PMID: 26054890 PMCID: PMC4521095 DOI: 10.1007/s00259-015-3087-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 05/11/2015] [Indexed: 12/14/2022]
Abstract
Purpose Epicardial adipose tissue (EAT) has been linked to coronary artery disease (CAD) and coronary microvascular dysfunction. However, its injurious effect may also impact the underlying myocardium. This study aimed to determine the impact of obesity on the quantitative relationship between left ventricular mass (LVM), EAT and coronary microvascular function. Methods A total of 208 (94 men, 45 %) patients evaluated for CAD but free of coronary obstructions underwent quantitative [15O]H2O hybrid positron emission tomography (PET)/CT imaging. Coronary microvascular resistance (CMVR) was calculated as the ratio of mean arterial pressure to hyperaemic myocardial blood flow. Results Obese patients [body mass index (BMI) > 25, n = 133, 64 % of total] had more EAT (125.3 ± 47.6 vs 93.5 ± 42.1 cc, p < 0.001), a higher LVM (130.1 ± 30.4 vs 114.2 ± 29.3 g, p < 0.001) and an increased CMVR (26.6 ± 9.1 vs 22.3 ± 8.6 mmHg×ml−1×min−1×g−1, p < 0.01) as compared to nonobese patients. Male gender (β = 40.7, p < 0.001), BMI (β = 1.61, p < 0.001), smoking (β = 6.29, p = 0.03) and EAT volume (β = 0.10, p < 0.01) were identified as independent predictors of LVM. When grouped according to BMI status, EAT was only independently associated with LVM in nonobese patients. LVM, hypercholesterolaemia and coronary artery calcium score were independent predictors of CMVR. Conclusion EAT volume is associated with LVM independently of BMI and might therefore be a better predictor of cardiovascular risk than BMI. However, EAT volume was not related to coronary microvascular function after adjustments for LVM and traditional risk factors. Electronic supplementary material The online version of this article (doi:10.1007/s00259-015-3087-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M. J. Bakkum
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - I. Danad
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - M. A. J. Romijn
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - W. J. A. Stuijfzand
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - R. M. Leonora
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - I. I. Tulevski
- />Cardiology Centers of the Netherlands, Amsterdam, The Netherlands
| | - G. A. Somsen
- />Cardiology Centers of the Netherlands, Amsterdam, The Netherlands
| | - A. A. Lammertsma
- />Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - C. van Kuijk
- />Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - A. C. van Rossum
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| | - P. G. Raijmakers
- />Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - P. Knaapen
- />Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
18
|
|
19
|
Raaphorst RM, Windhorst AD, Elsinga PH, Colabufo NA, Lammertsma AA, Luurtsema G. Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier. Clin Pharmacol Ther 2015; 97:362-71. [PMID: 25669763 DOI: 10.1002/cpt.73] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 01/06/2015] [Indexed: 02/03/2023]
Abstract
ABC transporters protect the brain by transporting neurotoxic compounds from the brain back into the blood. P-glycoprotein (P-gp) is the most investigated ABC (efflux) transporter, as it is implicated in neurodegenerative diseases such as Alzheimer's disease. Altered function of P-gp can be studied in vivo, using Positron Emission Tomography (PET). To date, several radiopharmaceuticals have been developed to image P-gp function in vivo. So far, attempts to image expression levels of P-gp using radiolabeled P-gp inhibitors have not been successful. Improved knowledge of compound behavior toward P-gp from in vitro studies should increase predictability of in vivo outcome.
Collapse
Affiliation(s)
- R M Raaphorst
- Department of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
20
|
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis 2014; 1:181-202. [PMID: 26478889 PMCID: PMC4606938 DOI: 10.14283/jpad.2014.32] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Alzheimer's disease (AD) is a slowly progressing non-linear dynamic brain disease in which pathophysiological abnormalities, detectable in vivo by biological markers, precede overt clinical symptoms by many years to decades. Use of these biomarkers for the detection of early and preclinical AD has become of central importance following publication of two international expert working group's revised criteria for the diagnosis of AD dementia, mild cognitive impairment (MCI) due to AD, prodromal AD and preclinical AD. As a consequence of matured research evidence six AD biomarkers are sufficiently validated and partly qualified to be incorporated into operationalized clinical diagnostic criteria and use in primary and secondary prevention trials. These biomarkers fall into two molecular categories: biomarkers of amyloid-beta (Aβ) deposition and plaque formation as well as of tau-protein related hyperphosphorylation and neurodegeneration. Three of the six gold-standard ("core feasible) biomarkers are neuroimaging measures and three are cerebrospinal fluid (CSF) analytes. CSF Aβ1-42 (Aβ1-42), also expressed as Aβ1-42 : Aβ1-40 ratio, T-tau, and P-tau Thr181 & Thr231 proteins have proven diagnostic accuracy and risk enhancement in prodromal MCI and AD dementia. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow-up. Magnetic resonance imaging (MRI) at increasing field strength and resolution allows detecting the evolution of distinct types of structural and functional abnormality pattern throughout early to late AD stages. Anatomical or volumetric MRI is the most widely used technique and provides local and global measures of atrophy. The revised diagnostic criteria for "prodromal AD" and "mild cognitive impairment due to AD" include hippocampal atrophy (as the fourth validated biomarker), which is considered an indicator of regional neuronal injury. Advanced image analysis techniques generate automatic and reproducible measures both in regions of interest, such as the hippocampus and in an exploratory fashion, observer and hypothesis-indedendent, throughout the entire brain. Evolving modalities such as diffusion-tensor imaging (DTI) and advanced tractography as well as resting-state functional MRI provide useful additionally useful measures indicating the degree of fiber tract and neural network disintegration (structural, effective and functional connectivity) that may substantially contribute to early detection and the mapping of progression. These modalities require further standardization and validation. The use of molecular in vivo amyloid imaging agents (the fifth validated biomarker), such as the Pittsburgh Compound-B and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) (as the sixth validated biomarker) support the detection of early AD pathological processes and associated neurodegeneration. How to use, interpret, and disclose biomarker results drives the need for optimized standardization. Multimodal AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping fashion. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. AD biomarkers can be combined to increase accuracy or risk. A list of genetic risk factors is increasingly included in secondary prevention trials to stratify and select individuals at genetic risk of AD. Although most of these biomarker candidates are not yet qualified and approved by regulatory authorities for their intended use in drug trials, they are nonetheless applied in ongoing clinical studies for the following functions: (i) inclusion/exclusion criteria, (ii) patient stratification, (iii) evaluation of treatment effect, (iv) drug target engagement, and (v) safety. Moreover, novel promising hypothesis-driven, as well as exploratory biochemical, genetic, electrophysiological, and neuroimaging markers for use in clinical trials are being developed. The current state-of-the-art and future perspectives on both biological and neuroimaging derived biomarker discovery and development as well as the intended application in prevention trials is outlined in the present publication.
Collapse
Affiliation(s)
- E Cavedo
- Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Institut du Cerveau et de la Moelle épinière (ICM), UMR S 1127, Hôpital de la Pitié-Salpétrière Paris & CATI multicenter neuroimaging platform, France; Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio Fatebenefratelli Brescia, Italy
| | - S Lista
- AXA Research Fund & UPMC Chair; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| | - Z Khachaturian
- The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020), Potomac, MD, USA
| | - P Aisen
- Department of Neurosciences, University of California San Diego, San Diego, CA, USA
| | - P Amouyel
- Inserm, U744, Lille, 59000, France; Université Lille 2, Lille, 59000, France; Institut Pasteur de Lille, Lille, 59000, France; Centre Hospitalier Régional Universitaire de Lille, Lille, 59000, France
| | - K Herholz
- Institute of Brain, Behaviour and Mental Health, University of Manchester, UK
| | - C R Jack
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - R Sperling
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - J Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, Nevada 89106, USA
| | - K Blennow
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
| | - S O'Bryant
- Department of Internal Medicine, Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - G B Frisoni
- IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva, Geneva, Switzerland
| | | | - M Kivipelto
- Karolinska Institutet Alzheimer Research Center, NVS, Stockholm, Sweden
| | - W Klunk
- Department of Psychiatry, University of Pittsburgh School of Medicine, USA; Department of Neurology, University of Pittsburgh School of Medicine, USA
| | - K Broich
- Federal Institute of Drugs and Medical Devices (BfArM), Bonn, Germany
| | - S Andrieu
- Inserm UMR1027, Université de Toulouse III Paul Sabatier, Toulouse, France; Public health department, CHU de Toulouse
| | - M Thiebaut de Schotten
- Natbrainlab, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, King's College London, London, UK; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (ICM), UMRS 1127 Paris, France; Inserm, U 1127, Paris, France; CNRS, UMR 7225, Paris, France
| | - J-F Mangin
- CEA UNATI, Neurospin, CEA Gif-sur-Yvette, France & CATI multicenter neuroimaging platform
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
| | - K Johnson
- Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - S Teipel
- Department of Psychosomatic Medicine, University of Rostock, and DZNE, German Center for Neurodegenerative Diseases, Rostock, Germany
| | - A Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne Germany
| | - A Bokde
- Cognitive Systems Group, Discipline of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - O Colliot
- Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, U1127, F-75013, Paris, France; CNRS, UMR 7225 ICM, 75013, Paris, France; Inria, Aramis project-team, Centre de Recherche Paris-Rocquencourt, France
| | - H Bakardjian
- Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpétrière University Hospital, Paris, France; IHU-A-ICM - Paris Institute of Translational Neurosciences, Paris, France
| | - H Zetterberg
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, Queen Square, London, UK
| | - B Dubois
- Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| | - B Vellas
- Inserm UMR1027, University of Toulouse, Toulouse, France
| | - L S Schneider
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - H Hampel
- AXA Research Fund & UPMC Chair; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| |
Collapse
|
21
|
Heijtel DFR, Mutsaerts HJMM, Bakker E, Schober P, Stevens MF, Petersen ET, van Berckel BNM, Majoie CBLM, Booij J, van Osch MJP, Vanbavel E, Boellaard R, Lammertsma AA, Nederveen AJ. Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: a head-to-head comparison with ¹⁵O H₂O positron emission tomography. Neuroimage 2014; 92:182-92. [PMID: 24531046 DOI: 10.1016/j.neuroimage.2014.02.011] [Citation(s) in RCA: 114] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2013] [Revised: 01/28/2014] [Accepted: 02/03/2014] [Indexed: 11/18/2022] Open
Abstract
Measurements of the cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) provide useful information about cerebrovascular condition and regional metabolism. Pseudo-continuous arterial spin labeling (pCASL) is a promising non-invasive MRI technique to quantitatively measure the CBF, whereas additional hypercapnic pCASL measurements are currently showing great promise to quantitatively assess the CVR. However, the introduction of pCASL at a larger scale awaits further evaluation of the exact accuracy and precision compared to the gold standard. (15)O H₂O positron emission tomography (PET) is currently regarded as the most accurate and precise method to quantitatively measure both CBF and CVR, though it is one of the more invasive methods as well. In this study we therefore assessed the accuracy and precision of quantitative pCASL-based CBF and CVR measurements by performing a head-to-head comparison with (15)O H₂O PET, based on quantitative CBF measurements during baseline and hypercapnia. We demonstrate that pCASL CBF imaging is accurate during both baseline and hypercapnia with respect to (15)O H₂O PET with a comparable precision. These results pave the way for quantitative usage of pCASL MRI in both clinical and research settings.
Collapse
Affiliation(s)
- D F R Heijtel
- Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands.
| | - H J M M Mutsaerts
- Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
| | - E Bakker
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - P Schober
- Department of Anesthesiology, VU University Medical Center, Amsterdam, The Netherlands
| | - M F Stevens
- Department of Anesthesiology, Academic Medical Center, Amsterdam, The Netherlands
| | - E T Petersen
- Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - B N M van Berckel
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - C B L M Majoie
- Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
| | - J Booij
- Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - M J P van Osch
- C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - E Vanbavel
- Department of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, The Netherlands
| | - R Boellaard
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - A A Lammertsma
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - A J Nederveen
- Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
22
|
Affiliation(s)
- R Boellaard
- Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, The Netherlands,
| | | | | | | |
Collapse
|
23
|
van der Veldt AAM, Smit EF, Comans EFI, Lammertsma AA. Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy. Strahlenther Onkol 2013; 190:221-2. [PMID: 24306065 DOI: 10.1007/s00066-013-0487-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Accepted: 10/18/2013] [Indexed: 11/30/2022]
Affiliation(s)
- A A M van der Veldt
- Department of Internal Medicine, VU University Medical Center, 1007 MB, Amsterdam, Netherlands,
| | | | | | | |
Collapse
|
24
|
Güçlü A, Germans T, Witjas-Paalberends ER, Stienen GJM, Brouwer WP, Harms HJ, Marcus JT, Vonk ABA, Stooker W, Yilmaz A, Klein P, Ten Berg JM, Kluin J, Asselbergs FW, Lammertsma AA, Knaapen P, van Rossum AC, van der Velden J. ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study). Neth Heart J 2013; 21:567-71. [PMID: 24114686 PMCID: PMC3833912 DOI: 10.1007/s12471-013-0478-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Introduction Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease mostly due to mutations in genes encoding sarcomeric proteins. HCM is characterised by asymmetric hypertrophy of the left ventricle (LV) in the absence of another cardiac or systemic disease. At present it lacks specific treatment to prevent or reverse cardiac dysfunction and hypertrophy in mutation carriers and HCM patients. Previous studies have indicated that sarcomere mutations increase energetic costs of cardiac contraction and cause myocardial dysfunction and hypertrophy. By using a translational approach, we aim to determine to what extent disturbances of myocardial energy metabolism underlie disease progression in HCM. Methods Hypertrophic obstructive cardiomyopathy (HOCM) patients and aortic valve stenosis (AVS) patients will undergo a positron emission tomography (PET) with acetate and cardiovascular magnetic resonance imaging (CMR) with tissue tagging before and 4 months after myectomy surgery or aortic valve replacement + septal biopsy. Myectomy tissue or septal biopsy will be used to determine efficiency of sarcomere contraction in-vitro, and results will be compared with in-vivo cardiac performance. Healthy subjects and non-hypertrophic HCM mutation carriers will serve as a control group. Endpoints Our study will reveal whether perturbations in cardiac energetics deteriorate during disease progression in HCM and whether these changes are attributed to cardiac remodelling or the presence of a sarcomere mutation per se. In-vitro studies in hypertrophied cardiac muscle from HOCM and AVS patients will establish whether sarcomere mutations increase ATP consumption of sarcomeres in human myocardium. Our follow-up imaging study in HOCM and AVS patients will reveal whether impaired cardiac energetics are restored by cardiac surgery.
Collapse
Affiliation(s)
- A Güçlü
- Department of Cardiology, Institute for Cardiovascular Research (ICaR-VU, VU University Medical Center, ZH 5F-13, PO Box 7057, 1007MB, Amsterdam, the Netherlands,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Harms HJ, Nesterov SV, Han C, Danad I, Leonora R, Raijmakers PG, Lammertsma AA, Knuuti J, Knaapen P. Comparison of clinical non-commercial tools for automated quantification of myocardial blood flow using oxygen-15-labelled water PET/CT. Eur Heart J Cardiovasc Imaging 2013; 15:431-41. [DOI: 10.1093/ehjci/jet177] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
De Haan S, Rijnierse MT, Harms HJ, Allaart CP, Huisman M, Van Rossum AC, Lammertsma AA, Knaapen P. PET/CT assessed myocardial innervation and perfusion mismatch correlates with heterogenic scar size assessed with CMR. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Guclu A, Knaapen P, Harms HJ, Vermeer AMC, Wilde AAM, Lammertsma AA, Van Rossum AC, Germans T, Van Der Velden J. Myocardial energetic impairment differs in pre-hypertrophic carriers with mutations in MYH7 and MYBPC3 - a PET and MRI study. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Rijnierse MT, Allaart CP, De Haan S, Harms HJ, Wu L, Danad I, Van Rossum AC, Lammertsma AA, Knaapen P. Inducibility of ventricular arrhythmias is related with impaired hyperaemic myocardial blood flow assessed with [15O]H2O PET in patients with ischaemic cardiomyopathy. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Teunissen PF, Danad I, Hollander MR, Timmer SA, Raijmakers PG, Lammertsma AA, Van Rossum AC, Van Royen N, Knaapen P. Coronary flow reserve is impaired in infarcted as well as normal myocardium following successful PCI in patients with acute myocardial infarction. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Rijbroek A, Boellaard R, Vriens EM, Lammertsma AA, Rauwerda JA. Comparison of transcranial Doppler ultrasonography and positron emission tomography using a three-dimensional template of the middle cerebral artery. Neurol Res 2013; 31:52-9. [DOI: 10.1179/174313208x325191] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
31
|
Gent YY, Weijers K, Molthoff CF, Windhorst AD, Huisman MC, Smith DE, Kularatne SA, Jansen G, Low PS, Lammertsma AA, van der Laken CJ. AB0761 Synthesis and evaluation of the novel folate receptor ligand [18f]fluoro-peg-folate for macrophage targeting in a rat model of arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.3083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Luurtsema G, Windhorst AD, Herscheid JDM, Molthoff CFM, Boellaard R, Smit H, Schinkel AH, Lammertsma AA, Franssen EJF. Synthesis and pet-studies of (R)-and (S)-[11C]verapamil for measuring PGP function in MDR1A(+/+)/B(+/+) and MDR1A(-/-)/B(-/-) mice. J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.25804401110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
33
|
Nanka O, Krejci E, Pesevski Z, Sedmera D, Smart N, Rossdeutsch A, Dube KN, Riegler J, Price AN, Taylor A, Muthurangu V, Turner M, Lythgoe MF, Riley PR, Kryvorot S, Vladimirskaya T, Shved I, Schwarzl M, Seiler S, Huber S, Steendijk P, Maechler H, Truschnig-Wilders M, Pieske B, Post H, Caprio C, Baldini A, Chiavacci E, Dolfi L, Verduci L, Meghini F, Cremisi F, Pitto L, Kuan TC, Chen MC, Yang TH, Wu WT, Lin CS, Rai H, Kumar S, Sharma AK, Mastana S, Kapoor A, Pandey CM, Agrawal S, Sinha N, Orlowska-Baranowska EH, Placha G, Gora J, Baranowski R, Abramczuk E, Hryniewiecki T, Gaciong Z, Verschuren JJW, Wessels JAM, Trompet S, Stott DJ, Sattar N, Buckley B, Guchelaar HJ, Jukema JW, Gharanei M, Hussain A, Mee CJ, Maddock HL, Wijnen WJ, Van Den Oever S, Van Der Made I, Hiller M, Tijsen AJ, Pinto YM, Creemers EE, Nikulina SUY, Chernova A, Petry A, Rzymski T, Kracun D, Riess F, Pike L, Harris AL, Gorlach A, Katare R, Oikawa A, Riu F, Beltrami AP, Cesseli D, Emanueli C, Madeddu P, Zaglia T, Milan G, Franzoso M, Pesce P, Sarais C, Sandri M, Mongillo M, Butler TJ, Seymour AML, Ashford D, Jaffre F, Bussen M, Ferrara N, Koch WJ, Leosco D, Akhmedov A, Klingenberg R, Brokopp C, Hof D, Zoller S, Corti R, Gay S, Flohrschutz I, Von Eckardstein A, Hoerstrup SP, Luescher TF, Heijman J, Zaza A, Johnson DM, Rudy Y, Peeters RLM, Volders PGA, Westra RL, Martin GR, Morais CAS, Oliveira SHV, Brandao FC, Gomes IF, Lima LM, Fujita S, Okamoto R, Taniguchi M, Konishi K, Goto I, Engelhardt S, Sugimoto K, Nakamura M, Shiraki K, Buechler C, Ito M, Kararigas G, Nguyen BT, Jarry H, Regitz-Zagrosek V, Van Bilsen M, Daniels A, Munts C, Janssen BJA, Van Der Vusse GJ, Van Nieuwenhoven FA, Montalvo C, Villar AV, Merino D, Garcia R, Llano M, Ares M, Hurle MA, Nistal JF, Dembinska-Kiec A, Beata Kiec-Wilk BKW, Anna Polus AP, Urszula Czech UC, Tatiana Konovaleva TK, Gerd Schmitz GS, Bertrand L, Balteau M, Timmermans A, Viollet B, Sakamoto K, Feron O, Horman S, Vanoverschelde JL, Beauloye C, De Meester C, Martinez E, Martin R, Miana M, Jurado R, Gomez-Hurtado N, Bartolome MV, San Roman JA, Lahera V, Nieto ML, Cachofeiro V, Rochais F, Sturny R, Mesbah K, Miquerol L, Kelly RG, Messaoudi S, Gravez B, Tarjus A, Pelloux V, Samuel JL, Delcayre C, Launay JM, Clement K, Farman N, Jaisser F, Hadyanto L, Castellani C, Vescovo G, Ravara B, Tavano R, Pozzobon M, De Coppi P, Papini E, Vettor R, Thiene G, Angelini A, Meloni M, Caporali A, Cesselli D, Fortunato O, Avolio E, Madeddu P, Beltrami AP, Emanueli C, Schindler R, Simrick S, Brand T, Dube KN, Riley PR, Smart NS, Oikawa A, Katare R, Herman A, Emanueli C, Madeddu P, Roura Ferrer S, Rodriguez Bago J, Soler-Botija C, Pujal JM, Galvez-Monton C, Prat-Vidal C, Llucia-Valldeperas A, Blanco J, Bayes-Genis A, Foldes G, Maxime M, Ali NN, Schneider MD, Harding SE, Reni C, Mangialardi G, Caporali A, Meloni M, Emanueli C, Madeddu P, De Pauw A, Sekkali B, Friart A, Ding H, Graffeuil A, Catalucci D, Balligand JL, Azibani F, Tournoux F, Schlossarek S, Polidano E, Fazal L, Merval R, Carrier L, Chatziantoniou C, Samuel JL, Delcayre C, Buyandelger B, Linke W, Zou P, Kostin S, Ku C, Felkin L, Birks E, Barton P, Sattler M, Knoell R, Schroder K, Benkhoff S, Shimokawa H, Grisk O, Brandes RP, Parepa IR, Mazilu L, Suceveanu AI, Suceveanu A, Rusali L, Cojocaru L, Matei L, Toringhibel M, Craiu E, Pires AL, Pinho M, Pinho S, Sena C, Seica R, Leite-Moreira A, Zaglia T, Milan G, Franzoso M, Dabroi F, Pesce P, Schiaffino S, Sandri M, Mongillo M, Kiseleva E, Krukov N, Nikitin O, Ardatova L, Mourouzis I, Pantos C, Kokkinos AD, Cokkinos DV, Scoditti E, Massaro M, Carluccio MA, Pellegrino M, Calabriso N, Gastaldelli A, Storelli C, De Caterina R, Lindner D, Zietsch C, Schultheiss HP, Tschope C, Westermann D, Everaert BR, Nijenhuis VJ, Reith FCM, Hoymans VY, Timmermans JP, Vrints CJ, Simova I, Mateev H, Katova T, Haralanov L, Dimitrov N, Mironov N, Golitsyn SP, Sokolov SF, Yuricheva YUA, Maikov EB, Shlevkov NB, Rosenstraukh LV, Chazov EI, Radosinska J, Knezl V, Benova T, Slezak J, Urban L, Tribulova N, Virag L, Kristof A, Kohajda ZS, Szel T, Husti Z, Baczko I, Jost N, Varro A, Sarusi A, Farkas AS, Orosz SZ, Forster T, Varro A, Farkas A, Zakhrabova-Zwiauer OM, Hardziyenka M, Nieuwland R, Tan HL, Raaijmakers AJA, Bourgonje VJA, Kok GJM, Van Veen AAB, Anderson ME, Vos MA, Bierhuizen MFA, Benes J, Sebestova B, Sedmera D, Ghouri IA, Kemi OJ, Kelly A, Burton FL, Smith GL, Bourgonje VJA, Vos MA, Ozdemir S, Acsai K, Doisne N, Van Der Nagel R, Beekman HDM, Van Veen TAB, Sipido KR, Antoons G, Harmer SC, Mohal JS, Kemp D, Tinker A, Beech D, Burley DS, Cox CD, Wann KT, Baxter GF, Wilders R, Verkerk A, Fragkiadaki P, Germanakis G, Tsarouchas K, Tsitsimpikou C, Tsardi M, George D, Tsatsakis A, Rodrigues P, Barros C, Najmi AK, Khan V, Akhtar M, Pillai KK, Mujeeb M, Aqil M, Bayliss CR, Messer AE, Leung MC, Ward D, Van Der Velden J, Poggesi C, Redwood CS, Marston S, Vite A, Gandjbakhch E, Gary F, Fressart V, Leprince P, Fontaine G, Komajda M, Charron P, Villard E, Falcao-Pires I, Gavina C, Hamdani N, Van Der Velden J, Stienen GJM, Niessens HWM, Leite-Moreira AF, Paulus WJ, Messer AE, Marston S, Memo M, Leung MC, Bayliss CR, Memo M, Messer AE, Marston SB, Vafiadaki E, Qian J, Arvanitis DA, Sanoudou D, Kranias EG, Elmstedt N, Lind B, Ferm-Widlund K, Westgren M, Brodin LA, Mansfield C, West T, Ferenczi M, Wijnker PJM, Foster DB, Coulter A, Frazier A, Murphy AM, Stienen GJM, Van Der Velden J, Shah M, Sikkel MB, Desplantez T, Collins TP, O' Gara P, Harding SE, Lyon AR, Macleod KT, Ottesen AH, Louch WE, Carlson C, Landsverk OJB, Stridsberg M, Sjaastad I, Oie E, Omland T, Christensen G, Rosjo H, Cartledge J, Clark LA, Ibrahim M, Siedlecka U, Navaratnarajah M, Yacoub MH, Camelliti P, Terracciano CM, Chester A, Gonzalez-Tendero A, Torre I, Garcia-Garcia F, Dopazo J, Gratacos E, Taylor D, Bhandari S, Seymour AM, Fliegner D, Jost J, Bugger H, Ventura-Clapier R, Regitz-Zagrosek V, Carpi A, Campesan M, Canton M, Menabo R, Pelicci PG, Giorgio M, Di Lisa F, Hancock M, Venturini A, Al-Shanti N, Stewart C, Ascione R, Angelini G, Suleiman MS, Kravchuk E, Grineva E, Galagudza M, Kostareva A, Bairamov A, Krychtiuk KA, Watzke L, Kaun C, Demyanets S, Pisoni J, Kastl SP, Huber K, Maurer G, Wojta J, Speidl WS, Varga ZV, Farago N, Zvara A, Kocsis GF, Pipicz M, Csonka C, Csont T, Puskas GL, Ferdinandy P, Klevstigova M, Silhavy J, Manakov D, Papousek F, Novotny J, Pravenec M, Kolar F, Novakova O, Novak F, Neckar J, Barallobre-Barreiro J, Didangelos A, Yin X, Fernandez-Caggiano M, Drozdov I, Willeit P, Domenech N, Mayr M, Lemoine S, Allouche S, Coulbault L, Galera P, Gerard JL, Hanouz JL, Suveren E, Whiteman M, Baxter GF, Studneva IM, Pisarenko O, Shulzhenko V, Serebryakova L, Tskitishvili O, Timoshin A, Fauconnier J, Meli AC, Thireau J, Roberge S, Lompre AM, Jacotot E, Marks AM, Lacampagne A, Dietel B, Altendorf R, Daniel WG, Kollmar R, Garlichs CD, Verduci L, Parente V, Balasso S, Pompilio G, Colombo G, Milano G, Squadroni L, Cotelli F, Pozzoli O, Capogrossi MC, Ajiro Y, Saegusa N, Iwade K, Giles WR, Stafforini DM, Spitzer KW, Sirohi R, Candilio L, Babu G, Roberts N, Lawrence D, Sheikh A, Kolvekar S, Yap J, Hausenloy DJ, Yellon DM, Aslam M, Rohrbach S, Schlueter KD, Piper HM, Noll T, Guenduez D, Malinova L, Ryabukho VP, Lyakin DV, Denisova TP, Montoro-Garcia S, Shantsila E, Lip GYH, Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Kramkowski K, Mogielnicki A, Nowakowska M, Buczko W, Stancheva N, Mekenyan E, Gospodinov K, Tisheva S, Darago A, Rutkai I, Kalasz J, Czikora A, Orosz P, Bjornson HD, Edes I, Papp Z, Toth A, Riches K, Warburton P, O'regan DJ, Ball SG, Turner NA, Wood IC, Porter KE, Kogaki S, Ishida H, Nawa N, Takahashi K, Baden H, Ichimori H, Uchikawa T, Mihara S, Miura K, Ozono K, Lugano R, Padro T, Garcia-Arguinzonis M, Badimon L, Yin X, Ferraro F, Viner R, Ho J, Cutler D, Mayr M, Matchkov V, Aalkjaer C, Mangialardi G, Katare R, Oikawa A, Madeddu P, Krijnen PAJ, Hahn NE, Kholova I, Sipkens JA, Van Alphen FP, Simsek S, Schalkwijk CG, Van Buul JD, Van Hinsbergh VWM, Niessen HWM, Simova I, Katova T, Haralanov L, Caro CG, Seneviratne A, Monaco C, Hou D, Singh J, Gilson P, Burke MG, Heraty KB, Krams R, Coppola G, Albrecht K, Schgoer W, Wiedemann D, Bonaros N, Steger C, Theurl M, Stanzl U, Kirchmair R, Amadesi S, Fortunato O, Reni C, Katare R, Meloni M, Ascione R, Spinetti G, Cangiano E, Valgimigli M, Madeddu P, Caporali A, Meloni M, Miller AM, Cardinali A, Vierlinger K, Fortunato O, Spinetti G, Madeddu P, Emanueli C, Pagano G, Liccardo D, Zincarelli C, Femminella GD, Lymperopoulos A, De Lucia C, Koch WJ, Leosco D, Rengo G, Hinkel R, Husada W, Trenkwalder T, Di Q, Lee S, Petersen B, Bock-Marquette I, Niemann H, Di Maio M, Kupatt C, Nourian M, Yassin Z, Kelishadi R, Nourian M, Kelishadi R, Yassin Z, Memarian SH, Heidari A, Leuner A, Poitz DM, Brunssen C, Ravens U, Strasser RH, Morawietz H, Vogt F, Grahl A, Flege C, Marx N, Borinski M, De Geest B, Jacobs F, Muthuramu I, Gordts SC, Van Craeyveld E, Herijgers P, Weinert S, Poitz DM, Medunjanin S, Herold J, Schmeisser A, Strasser RH, Braun-Dullaeus RC, Wagner AH, Moeller K, Adolph O, Schwarz M, Schwale C, Bruehl C, Nobiling R, Wieland T, Schneider SW, Hecker M, Cross A, Strom A, Cole J, Goddard M, Hultgardh-Nilsson A, Nilsson J, Mauri C, Monaco C, Mitkovskaya NP, Kurak TA, Oganova EG, Shkrebneva EI, Kot ZHN, Statkevich TV, Molica F, Burger F, Matter CM, Thomas A, Staub C, Zimmer A, Cravatt B, Pacher P, Steffens S, Blanco R, Sarmiento R, Parisi C, Fandino S, Blanco F, Gigena G, Szarfer J, Rodriguez A, Garcia Escudero A, Riccitelli MA, Wantha S, Simsekyilmaz S, Megens RT, Van Zandvoort MA, Liehn E, Zernecke A, Klee D, Weber C, Soehnlein O, Lima LM, Carvalho MG, Gomes KB, Santos IR, Sousa MO, Morais CAS, Oliveira SHV, Gomes IF, Brandao FC, Lamego MRA, Lima LM, Fornai L, Angelini A, Kiss A, Giskes F, Eijkel G, Fedrigo M, Valente ML, Thiene G, Heeren RMA, Grdinic A, Vojvodic D, Djukanovic N, Grdinic AG, Obradovic S, Majstorovic I, Rusovic S, Vucinic Z, Tavciovski D, Ostojic M, Lin CS, Kuan TC, Lai SC, Chen MY, Wu HT, Gouweleeuw L, Oberdorf-Maass SU, De Boer RA, Van Gilst WH, Maass AH, Van Gelder IC, Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Launay JM, Carrier L, Chatziantoniou C, Samuel JL, Delcayre C, Li C, Warren D, Shanahan CM, Zhang QP, Bye A, Vettukattil R, Aspenes ST, Giskeodegaard G, Gribbestad IS, Wisloff U, Bathen TF, Cubedo J, Padro T, Alonso R, Mata P, Badimon L, Ivic I, Vamos Z, Cseplo P, Kosa D, Torok O, Hamar J, Koller A, Norita K, De Noronha SV, Sheppard MN, Torre I, Amat-Roldan I, Iruretagoiena I, Psilodimitrakopoulos S, Gonzalez-Tendero A, Crispi F, Artigas D, Loza-Alvarez P, Gratacos E, Harrison JC, Smart SD, Besely EH, Kelly JR, Yao Y, Sammut IA, Hoepfner M, Kuzyniak W, Sekhosana E, Hoffmann B, Litwinski C, Pries A, Ermilov E, Fontoura D, Lourenco AP, Vasques-Novoa F, Pinto JP, Roncon-Albuquerque R, Leite-Moreira AF, Oyeyipo IP, Olatunji LA, Usman TO, Olatunji VA, Bacova B, Radosinska J, Viczenczova C, Knezl V, Dosenko V, Benova T, Goncalvesova E, Vanrooyen J, Tribulova N, Maulik SK, Seth S, Dinda AK, Jaiswal A, Mearini G, Khajetoorians D, Kraemer E, Gedicke-Hornung C, Precigout G, Eschenhagen T, Voit T, Garcia L, Lorain S, Carrier L, Mendes-Ferreira P, Maia-Rocha C, Adao R, Lourenco AP, Cerqueira RJ, Mendes MJ, Castro-Chaves P, De Keulenaer GW, Leite-Moreira AF, Bras-Silva C, Ruiter G, Wong YY, Lubberink M, Knaapen P, Raijmakers P, Lammertsma AA, Marcus JT, Westerhof N, Van Der Laarse WJ, Vonk-Noordegraaf A, Poitz DM, Steinbronn N, Koch E, Steiner G, Strasser RH, Berezin A, Lisovaya OA, Soldatova AM, Kuznetcov VA, Yenina TN, Rychkov AYU, Shebeko PV, Altara R, Hessel MHM, Hermans JJR, Janssen BJA, Blankesteijn WM, Soldatova AM, Kuznetcov VA, Yenina TN, Rychkov AYU, Shebeko PV, Berezin A, Berezina TA, Seden V, Bonanad C, Nunez J, Navarro D, Chilet MF, Sanchis F, Bodi V, Minana G, Chaustre F, Forteza MJ, Llacer A, Femminella GD, Rengo G, Galasso G, Zincarelli C, Liccardo D, Pagano G, De Lucia C. Poster session 3. Cardiovasc Res 2012. [DOI: 10.1093/cvr/cvr336] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Danad I, Raijmakers PG, Kamali P, Harms HJ, de Haan S, Lubberink M, van Kuijk C, Hoekstra OS, Lammertsma AA, Smulders YM, Heymans MW, Tulevski II, van Rossum AC, Knaapen P. Carotid artery intima-media thickness, but not coronary artery calcium, predicts coronary vascular resistance in patients evaluated for coronary artery disease. Eur Heart J Cardiovasc Imaging 2012; 13:317-23. [DOI: 10.1093/ehjci/jes038] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Wong YY, Raijmakers PG, Knaapen P, Lubberink M, Ruiter G, Marcus JT, Boonstra A, Lammertsma AA, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Supine-exercise-induced oxygen supply to the right myocardium is attenuated in patients with severe idiopathic pulmonary arterial hypertension. Heart 2011; 97:2069-74. [DOI: 10.1136/heartjnl-2011-300237] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
36
|
Dunet V, Dabiri A, Allenbach G, Goyeneche Achigar A, Waeber B, Feihl F, Heinzer R, Prior JO, Van Velzen JE, Schuijf JD, De Graaf FR, De Graaf MA, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Lankinen E, Saraste A, Noponen T, Klen R, Teras M, Kokki T, Kajander S, Pietila M, Ukkonen H, Knuuti J, Pazhenkottil AP, Nkoulou RN, Ghadri JR, Herzog BA, Buechel RR, Kuest SM, Wolfrum M, Gaemperli O, Husmann L, Kaufmann PA, Andreini D, Pontone G, Mushtaq S, Antonioli L, Bertella E, Formenti A, Cortinovis S, Ballerini G, Fiorentini C, Pepi M, Koh AS, Flores JS, Keng FYJ, Tan RS, Chua TSJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni AD, Tamborini G, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Ewe SH, Ng ACT, Delgado V, Schuijf J, Van Der Kley F, Colli A, De Weger A, Marsan NA, Schalij MJ, Bax JJ, Yiu KH, Ng AC, Delgado V, Ewe SH, Van Der Kley F, De Weger A, Kroft LJ, De Roos A, Schuijf JD, Bax JJ, Timmer SAJ, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, Ten Cate FJ, Russel IK, Lammertsma AA, Van Rossum AC, Wong YY, Lubberink M, Ruiter G, Raijmakers P, Knaapen P, Van Der Laarse WJ, Westerhof N, Greer C, Chokshi A, Jones M, Schaefle K, Bhatia K, Shimbo D, Schulze PC, Nakajima K, Okuda K, Matsuo S, Vonk-Noordegraaf A, Kirihara Y, Ishikawa T, Taki J, Yoshita M, Yamada M, Kinuya S, Salacata A, Keavey S, Chavarri V, Mills J, Youssef G, Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, Heo J, Iskandrian AE, Jain M, Lin B, Leung E, Walker A, Nkonde C, Wackers F, Bond S, Baskin A, Declerck J, Schindler T, Ratib O, Zaidi H, Jimenez-Santos M, Wisenberg G, Alexanderson Rosas E, Ricalde A, Soto ME, Mendoza G, Aguilar M, Romero E, Pena-Cabral MA, Jacome R, Meave A, Williams SP, Marriot C, Colice G, Mcardle JR, Lankford A, Kajdasz DK, Reed CR, Mazzanti M, Angelini L, Pimpini L, Angelozzi F, Ascoli G, Williams K, Perna GP, Jacobson A, Lessig HJ, Gerson MC, Cerqueira MD, Narula J, Ashikaga K, Akashi YJ, Kamijima R, Uematsu M, Etele J, Yoneyama K, Kida K, Suzuki K, Omiya K, Miyake Y, Flotats A, Bravo PE, Fukushima K, Chaudhry M, Merrill J, Dekemp RA, Bengel FM, Alonso Tello A, Rodriguez Palomares JF, Marti Aguasca G, Aguade Bruix S, Aliaga V, Mahia P, Gonzalez-Alujas T, Candell J, Evangelista A, Dasilva J, Garcia-Dorado D, Mlynarski R, Mlynarska A, Sosnowski M, Zerahn B, Hasbak P, Mortensen CE, Mathiesen HF, Andersson M, Nielsen D, Birnie D, Ferreira Santos L, Ferreira MJ, Ramos D, Moreira D, Cunha MJ, Albuquerque A, Moreira A, Oliveira Santos J, Costa G, Providencia LA, Beanlands RSB, Arita Y, Kihara S, Mitsusada N, Miyawaki M, Ueda H, Hiraoka H, Matsuzawa Y, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Thompson RC, Askew J, O'connor M, Jordan L, Ruter R, Gibbons R, Miller T, Depuey G, Wray R, Emmett L, Ng A, Allam AH, Sorensen N, Mansberg R, Kritharides L, Diego M, Ruano R, Albarran C, Martin De Arriba A, Gomez-Caminero F, Rosero A, Gonzalez T, Wann LS, Garcia-Talavera JR, Martin Luengo C, Majmundar H, Coats NP, Vernotico S, Doan JH, Hernandez TM, Evini M, Hepner AD, Ip TK, Nureldin AH, Miyamoto MI, Thomas GS, Chalela WA, Falcao AM, Azouri LO, Ramires JAF, Meneghetti JC, Manganelli F, Spadafora M, Varrella P, Adelmaksoub G, Peluso G, Sauro R, Di Lorenzo E, Rotondi F, Daniele S, Miletto P, Cuocolo A, Rijnders AJM, Hendrickx BW, Van Der Bruggen W, Badr I, America YGCJ, Thorley PJ, Chowdhury FU, Dickinson CJ, Sazonova SI, Proskokova IYU, Gusakova AM, Minin SM, Lishmanov YUB, Saushkin VV, Sutherland ML, Vallejo E, Rodriguez G, Roffe F, Ilarraza H, Bialostozky D, Kitsiou AN, Arsenos P, Tsiantis I, Charizopoulos S, Karas S, Sutherland JD, Aoki H, Kajinami K, Matsunari I, Koh AS, Flores JS, Keng FYJ, Chua TSJ, Vidal Perez RC, Garrido M, Pubul V, Miyamoto MI, Argibay S, Pena C, Pombo M, Ciobotaru AB, Sanchez-Salmon A, Ruibal Morell A, Gonzalez-Juanatey JR, Jimenez-Heffernan A, Lopez-Martin J, Sanchez De Mora E, Thomas GS, Ramos C, Salgado C, Lopez-Aguilar R, Rodriguez-Gomez E, Roa J, Martinez B, Tobaruela A, Pontillo D, Benvissuto F, Fiore Melacrinis F, Harms HJ, Maccafeo S, Scabbia EV, Schiavo R, Golzar Y, Gidea C, Golzar J, Fukuda H, Moroi M, Masai H, Kunimasa T, De Haan S, Nakazato R, Furuhashi T, Sugi K, Kaczmarska E, Kepka C, Dzielinska Z, Pracon R, Kryczka K, Kruk M, Pregowski J, Knaapen P, Petryka J, Mazurkiewicz L, Demkow M, Hayes Brown K, Alhaji M, Collado F, Kiriakos R, Maheshwari A, Schmidt S, Vashistha R, Huisman MC, Alexander S, Shanes J, Doukky R, Vavlukis M, Pop-Gorceva D, Kostova N, Peovska I, Majstorov V, Zdravkovska M, Stojanovski S, Schuit RC, Georgievska-Ismail LJ, Katsikis T, Theodorakos A, Kouzoumi A, Koutelou M, Yoshimura Y, Toyama T, Hoshizaki H, Ohshima S, Inoue M, Windhorst AD, Suzuki T, Rossi A, Uitterdijk A, Dijkshoorn M, Van Straten M, Van Der Giessen WJ, Krestin GP, De Feyter PJ, Duncker DJ, Merkus D, Lammertsma AA, Mollet N, Pan XB, Platsch G, Schindler T, Quercioli A, Zaidi H, Ratib O, Sunderland J, Tonge C, Arumugam P, Allaart C, Declerck JM, Dey T, Wieczorek H, Bippus R, Romijn RL, Backus BE, Verzijlbergen JF, Aach T, Lomsky M, Johansson L, Lubberink M, Marving J, Svensson S, Edenbrandt L, Pou JL, Esteves FP, Chen J, Raggi P, Folks R, Keidar Z, Askew JW, Einstein AJ, Verdes L, Campos L, Garcia EV, Lishmanov YU, Zavadovskiy K, Gulyaev V, Pankova A, Santos J, Carmona S, Henriksson I, Khawaja T, Prata A, Carrageta M, Santos AI, Harms HJ, Knaapen P, De Haan S, Lammertsma AA, Lubberink M, Van Tosh A, Faber TL, Greer C, Votaw JR, Reichek N, Palestro C, Nichols KJ, Timmer SAJ, Lubberink M, Dijkmans PA, Ten Berg JM, Ten Cate FJ, Van Rossum AC, Chokshi A, Lammertsma AA, Knaapen P, Yoshinaga K, Naya M, Katoh C, Manabe O, Yamada S, Iwano H, Chiba S, Tsutsui H, Jones M, Tamaki N, Vassiliadis I, Despotopoulos E, Kaitozis O, Hatzistamatiou E, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Schaefle K, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Thompson R, Hatch J, Zink M, Gu BS, Bae GD, Bhatia K, Dae CM, Min GH, Chun EJ, Choi SI, Pontone G, Andreini D, Bertella E, Mushtaq S, Bartorelli AL, Cortinovis S, Shimbo D, Annoni AD, Formenti A, Fiorentini C, Pepi M, Al-Mallah M, Kassem K, Khawaja O, Yerramasu A, Venuraju S, Atwal S, Schulze PC, Goodman D, Lipkin D, Lahiri A, Christiaens L, Bonnet B, Mergy J, Coisne D, Allal J, Dias Ferreira N, Leite D, Srivastava A, Rocha J, Carvalho M, Caeiro D, Bettencourt N, Braga P, Gama Ribeiro V, Hasbak P, Kristoffersen US, Lebech AM, Gutte H, Chettiar R, Ripa RS, Wiinberg N, Petersen CL, Jensen G, Kjaer A, Bai C, Conwell R, Old R, Chen J, Folks RD, Moody J, Verdes-Moreiras L, Manatunga D, Jacobson AF, Garcia EV, Zafrir N, Gutstein A, Mats I, Belzer D, Hasid Y, Solodky A, Weyman C, Yerramasu A, Venuraju S, Atwal S, Goodman D, Lipkin D, Lahiri A, Rehling M, Poulsen RH, Falborg L, Rasmussen JT, Natale D, Waehrens LN, Heegaard CW, Silvola JMU, Saraste A, Forsback S, Laine JO, Heinonen S, Ylaherttuala S, Roivainen A, Knuuti J, Bruni W, Broisat A, Ruiz M, Goodman NC, Dimastromatteo J, Glover DK, Hyafil F, Blackwell F, Pavon-Djavid G, Rouzet F, Louedec L, Liu Y, Sarda-Mantel L, Feldman LJ, Michel JB, Meddahi-Pelle A, Le Guludec D, Weyman C, Sinusas A, Tsatkin V, Liu YH, De Kemp R, Ficaro E, Slomka PJ, Declerck J, Pan XB, Klein R, Nakazato R, Germano G, Tonge C, Beanlands RS, Berman DS, Rohani A, Sinusas AJ, Akbari V, Salacata A, Keavey S, Mills J, Groothuis JGJ, Fransen M, Beek AM, Brinckman SL, Meijerink MR, Hofman MBM, Peix A, Van Kuijk C, Van Rossum AC, Campini R, Marcassa C, Calza P, Zoccarato O, Toyama T, Hoshizaki H, Kogure S, Yamashita E, Batista E, Murakami J, Kawaguchi R, Adachi H, Oshima S, Minin S, Lishmanov YU, Popov S, Saushkina YU, Savenkova G, Lebedev D, Cabrera LO, Georgoulias P, Giamouzis G, Tziolas N, Karayannis G, Alexandridis E, Zavos N, Koutrakis K, Rovithis D, Parisis C, Triposkiadis F, Padron K, Minin S, Lishmanov YU, Sazonova I, Saushkin V, Pankova A, Chernov V, Zaabar L, Bahri H, Hadj Ali S, Sellem A, Rodriguez L, Slim I, El Kadri N, Slimen H, Hammami H, Lucic S, Peter A, Tadic S, Nikoletic K, Jung R, Lucic M, Sainz B, Tagil K, Edenbrandt L, Jakobsson D, Lomsky M, Marving J, Svensson SE, Wollmer P, Hesse B, Leccisotti L, Indovina L, Mendoza V, Paraggio L, Calcagni ML, Giordano A, Mut F, Kapitan M, Paolino A, Nunez M, Henzlova M, Duvall WL, Sweeny J, Carrillo R, Croft L, Kulkarni N, Guma K, Daou D, Tawileh M, Coaguila C, Akashi Y, Ashikaga K, Takano M, Takai M, Fernandez Y, Koh S, Kida K, Suzuki K, Miyake F, Torun N, Durmus Altun G, Altun A, Kaya E, Saglam H, Jacobson A, Mena E, Matsuoka DT, Smanio P, Sanchez A, Bartolozzi C, Oliveira M, Padua D, Ponta G, Ponte A, Carneiro A, Thom A, Naum A, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, Ashrafi R, Garg P, Davis G, Bach-Gansmo T, Falcao A, Azouri LO, Chalela WA, Costa M, Bussolini F, Ramires JAF, Meneghetti JAC, Matsuo S, Nakajima K, Tobisaka M, Kleven-Madsen N, Okuda K, Kinuya S, Ferreira MJ, Correia E, Ramos D, Cunha MJ, Moreira A, Albuquerque A, Costa G, Providencia LA, Biermann M, Tio RA, Jansen JW, Van Der Vleuten PA, Willems TP, Zijlstra F, Dierckx RAIO, Slart RHJA, Sato M, Toyama T, Oshima S, Johnsen B, Taniguchi K, Kurabayashi M, Majstorov V, Pop Gjorcheva D, Vavlukis M, Zdravkovska M, Peovska I, Zdraveska-Kochovska M, Kostova N, Moriwaki K, Aase Husby J, Kawamura A, Watanabe K, Omura T, Sakabe S, Seko T, Kasai A, Ito M, Obana M, Akasaka T, Askew J, Rotevatn S, Hruska C, Truong D, Pletta C, Collins D, Tortorelli C, Rhodes D, Gibbons R, Miller T, O'connor M, Nasr GM, Nordrehaug JE, El-Prince M, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Schaap J, Tobaruela A, Martinez-Moeller A, Marinelli M, Weismueller S, Hillerer C, Jensen B, Schwaiger M, Nekolla SG, Nakajima K, Matsuo S, Kauling RM, Okuda K, Wakabayashi H, Tsukamoto K, Kinuya S, Nishimura T, Baker SMEA, Sirajul Haque KMHS, Siddique A, Krishna Banarjee S, Ahsan A, Post MC, Rahman F, Mukhlesur Rahman M, Parveen T, Lutfinnessa M, Nasreen F, Sano H, Toyama T, Adachi H, Naito S, Hoshizaki H, Rensing BJWM, Oshima S, Kurabayashi M, Harms HJ, De Haan S, Knaapen P, Schuit RC, Windhorst AD, Lammertsma AA, Allaart C, Lubberink M, Verzijlbergen JF, De Rimini ML, Borrelli G, Baldascino F, Calabro P, Maiello C, Russo A, Amarelli C, Muto P, Danad I, Raijmakers PG, Peix A, Appelman YE, Harms HJ, De Haan S, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Wong YY, Ruiter G, Sanchez J, Lubberink M, Knaapen P, Raijmakers P, Marcus JT, Boonstra A, Westerhof N, Van Der Laarse WJ, Vonk-Noordegraaf A, Ryzhkova DV, Kuzmina TV, Cabrera LO, Borodina OS, Trukshina MA, Kostina IS, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni A, Formenti A, Cortinovis S, Padron K, Bartorelli AL, Fiorentini C, Pepi M, Ishii K, Kunimasa T, Shiba M, Aikawa J, Hommel H, Feuchtner G, Pachinger O, Carrillo R, Friedrich G, Stel AM, Bettencourt N, Dias Ferreira N, Rocha J, Carvalho M, Leite D, Deckers JW, Gama V, De Graaf MA, Fernandez Y, Van Velzen JE, Ciarka A, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Schuijf JD, Bax JJ, Veltman CE, Mena E, De Graaf FR, Van Werkhoven JM, Jukema JW, Kroft LJ, De Roos A, Van Der Wall EE, Bax JJ, Schuijf JD, Ten Kate GJR, Neefjes LA, Giamouzis G, Rossi A, Weustink AC, Moelker A, Nieman K, Mollet NR, Krestin GP, Sijbrands EJ, De Feyter PJ, Mlynarski R, Mlynarska A, Tziolas N, Wilczek J, Sosnowski M, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Brito J, Cale R, Gaspar A, Georgoulias P, Machado FP, Roquette J, Alonso Tello A, Rodriguez Palomares JF, Llibre Pallares C, Abdul-Jawad Altisent O, Cuellar Calabria H, Mahia Casado P, Gonzalez-Alujas MT, Candell J, Karayannis G, Evangelista Masip A, Garcia-Dorado Garcia D, Tekabe Y, Shen X, Li Q, Luma J, Weisenberger D, Schmidt AM, Haubner R, Johnson L, Chamaidi A, Sleiman L, Thorn S, Hasu M, Thabet M, Dasilva JN, Dekemp RA, Beanlands RS, Whitman SC, Genovesi D, Giorgetti A, Zavos N, Gimelli A, Cannizzaro G, Giubbini R, Bertagna F, Fagioli G, Rossi M, Bonini R, Marzullo P, Paterson CA, Smith SA, Koutrakis K, Small AD, Goodfield NER, Martin W, Nekolla S, Sherif H, Saraste A, Reder S, Yu M, Schwaiger M, Gimelli A, Sitafidis G, Genovesi D, Kusch A, Giorgetti A, Marzullo P, Chen J, Chen C, Li D, Zou J, Lloyd MS, Cao K, Skoularigis J, Williams SP, Mcardle JR, Colice G, Lankford A, Kajdasz DK, Reed CR, Smith SA, Motherwell DW, Rice A, Paterson CA, Triposkiadis F, Small AD, Mccurrach GM, Goodfield NER, Cobbe SM, Petrie MC, Martin W, Ewe SH, Boogers MJ, Dibbets-Schneider P, Van Bommel RJ, Radovanovic S, Delgado V, Al Younis I, Van Der Hiel B, Schalij MJ, Van Der Wall E, Bax JJ, Mirza T, Raza M, Hashemizadeh H, Pollice PP, Djokovic A, Bonifazi MB, Pollice FP, Ferreira MJ, Santos L, Ramos D, Cunha MJ, Albuquerque A, Moreira A, Costa G, Providencia LA, Simic DV, Singh N, Krishna BA, Leccisotti L, Perna F, Lago M, Leo M, Pelargonio G, Bencardino G, Narducci ML, Casella M, Krotin M, Bellocci F, Giordano A, Kirac S, Yaylali O, Serteser M, Yaylali T, Okizaki A, Urano Y, Nakayama M, Ishitoya S, Savic-Radojevic A, Sato J, Ishikawa Y, Sakaguchi M, Nakagami N, Watanabe K, Aburano T, Solav SV, Bhandari R, Burrell S, Dorbala S, Pljesa-Ercegovac M, Leccisotti L, Bruno I, Caldarella C, Collarino A, Mattoli MV, Stefanelli A, Cannarile A, Maggi F, Giordano A, Soukhov V, Zdravkovic M, Bondarev S, Yalfimov A, Low CS, Notghi A, O'brien J, Khan M, Priyadharshan PP, Chandok G, Aziz T, Avison M, Saponjski J, Smith RA, Bulugahapitya DS, Vakhtangadze T, Todua F, Baramia M, Antelava G, Roche NC, Paule P, Kerebel S, Gil JM, Jelic S, Fourcade L, Tzonevska A, Tzvetkov K, Atanasova M, Parvanova V, Chakarova A, Piperkova E, Aktas A, Bahceci T, Yaman G, Simic T, Cinar A, Kocabas B, Kavak K, Gencoglu A, Muderrisoglu H, De Haan S, Knaapen P, Harms HJ, Lubberink M, Beek AM, Eckardt R, Lammertsma AA, Van Rossum AC, Allaart CP, Entok E, Simsek S, Akcay B, Ak I, Vardareli E, Stachura M, Kwasiborski PJ, Kjeldsen BJ, Horszczaruk GJ, Komar E, Cwetsch A, Nasr GM, Sliem H, Hayes Brown K, Alexander S, Green J, Zraik B, Jain S, Andersen LI, Aldaas F, Collado F, Alhaji M, Morales Demori R, Doukky R, Falcao A, Chalela WA, Azouri LO, Almeida ADJ, Ramires JAF, Haghfelt T, Meneghetti JC, Siqueira ME, Vieira E, Kelendjian J, Oliveira M, Alves F, Smanio P, Balogh I, Kerecsen G, Marosi E, Grupe P, Szelid ZS, Al-Mallah M, Sattar A, Swadia T, Chattahi J, Qureshi W, Khalid F, Peix A, Cabrera LO, Gonzalez A, Johansen A, Padron K, Carrillo R, Mena E, Fernandez Y, Hechavarria S, Rodriguez L, Takamura K, Fujimoto S, Nakanishi R, Yamashina S, Hesse B, Namiki A, Yamazaki J, Koshino K, Fukuda H, Hashikawa Y, Teramoto N, Hikake M, Ishikane S, Ikeda T, Iida H, Pena H, Dey T, Wieczorek H, Bippus R, Backus BE, Romijn RL, Verzijlbergen JF, Aach T, Takahashi Y, Oriuchi N, Higashino H, Cantinho G, Endo K, Mochizuki T, Murase K, Baali A, Moreno R, Chau M, Rousseau H, Nicoud F, Dolliner P, Brammen L, Wilk M, Steurer G, Traub-Weidinger T, Ubl P, Schaffarich P, Dobrozemsky G, Staudenherz A, Ozgen Kiratli M, Temelli B, Kanat NB, Aksoy T, Srour Y, Slavich GA, Piccoli G, Puppato M, Grillone S, Gasparini D, Danad I, Raijmakers PG, Appelman YE, Harms HJ, Van Kuijk C, Godinho F, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Dunet V, Perruchoud S, Poitry-Yamate C, Lepore M, Gruetter R, Zafrir N, Pedrazzini T, Prior JO, Anselm D, Anselm A, Atkins H, Renaud J, Dekemp R, Burwash I, Guo A, Williams K, Gutstein A, Beanlands R, Glover C, Vilardi I, Zangheri B, Calabrese L, Romano P, Bruno A, Barreiro Perez M, Martin Fernandez M, Fernandez Cimadevilla OC, Mats I, Leon Duran D, Florez Munoz JP, Velasco Alonso E, Luyando LH, Uusitalo VA, Kajander S, Saraste A, Luotolahti M, Wendelin-Saarenhovi M, Sundell J, Battler A, Raitakari O, Knuuti J, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Huidu S, Gadiraju R, Ghesani M, Uddin Q, Solodky A, Wosnitzer B, Takahashi N, Alhaj E, Legasto A, Abiri B, Elsaban K, El Khouly T, El Kammash T, Al Ghamdi A, Hommel H, Sari E, Feuchtner G, Pachinger O, Friedrich G, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Purvis JA, Hughes SM, Kyung Deok B, Singh N, Bon Seung K, Sang Geun Y, Chang Min D, Gwan Hong M, Vara A, Peters AM, De Belder A, Nair S, Ryan N, James R, Dizdarevic S, Depuey G, Friedman M, Wray R, Old R, Babla H, Chuanyong B, Maddahi J, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Aguade-Bruix S, Cuberas-Borros G, Pizzi MN, Sabate-Fernandez M, De Leon G, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Casset-Senon D, Edjlali-Goujon M, Alison D, Delhommais A, Cosnay P, Low CS, Notghi A, O'brien J, Tweddel AC, Bingham N, O Neil P, Harbinson M, Lindner O, Burchert W, Schaefers M, Marcassa C, Campini R, Calza P, Zoccarato O, Kisko A, Kmec J, Babcak M, Vereb M, Vytykacova M, Cencarik J, Gazdic P, Stasko J, Abreu A, Pereira E, Oliveira L, Colarinha P, Veloso V, Enriksson I, Proenca G, Delgado P, Rosario L, Sequeira J, Kosa I, Vassanyi I, Egyed CS, Kozmann GY, Morita S, Nanasato M, Nanbu I, Yoshida Y, Hirayama H, Allam A, Sharef A, Shawky I, Farid M, Mouden M, Ottervanger JP, Timmer JR, De Boer MJ, Reiffers S, Jager PL, Knollema S, Nasr GM, Mohy Eldin M, Ragheb M, Casans-Tormo I, Diaz-Exposito R, Hurtado-Mauricio FJ, Ruano R, Diego M, Gomez-Caminero F, Albarran C, Martin De Arriba A, Rosero A, Lopez R, Martin Luengo C, Garcia-Talavera JR, Laitinen IEK, Rudelius M, Weidl E, Henriksen G, Wester HJ, Schwaiger M, Pan XB, Schindler T, Quercioli A, Zaidi H, Ratib O, Declerck JM, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Meave A, Gonzalez J, Rouzet F, Bachelet L, Alsac JM, Suzuki M, Louedec L, Petiet A, Chaubet F, Letourneur D, Michel JB, Le Guludec D, Aktas A, Cinar A, Yaman G, Bahceci T, Kavak K, Gencoglu A, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Tobaruela A, Nesterov SV, Turta O, Maki M, Han C, Knuuti J, Daou D, Tawileh M, Chamouine SO, Coaguila C, Aguade-Bruix S, Mariscal-Labrador E, Cuberas-Borros G, Sabate-Fernandez M, Pizzi MN, Kisiel-Gonzalez N, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Daou D, Tawileh M, Coaguila C, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Cale R, Brito J, Gaspar A, Machado FP, Roquette J, Alexanderson Rosas E, Jimenez-Santos M, Martinez M, Melendez G, Kimura E, Romero E, Pena-Cabral MA, Jacome R, Ochoa JM, Meave A, Alessio AM, Patel A, Lautamaki R, Bengel FM, Bassingthwaighte JB, Caldwell JH, Rahbar K, Seifarth H, Schafers M, Stegger L, Spieker T, Hoffmeier A, Maintz D, Scheld H, Schober O, Weckesser M, Aoki H, Matsunari I, Kajinami K, Martin Fernandez M, Barreiro Perez M, Fernandez Cimadevilla OV, Leon Duran D, Velasco Alonso E, Florez Munoz JP, Luyando LH, Ghadri JR, Pazhenkottil AP, Nkoulou RN, Husmann L, Buechel RR, Herzog BA, Wolfrum M, Gaemperli O, Templin C, Kaufmann PA, De Graaf FR, Schuijf JD, Veltman CE, Van Velzen JE, Kroft LJ, De Roos A, Reiber JHC, Jukema JW, Van Der Wall EE, Bax JJ, Venuraju S, Yerramasu A, Atwal S, Lahiri A, Kunimasa T, Shiba M, Ishii K, Aikawa J, Van Velzen JE, Schuijf JD, De Graaf FR, Kroner ESJ, Kroft LJ, De Roos A, Schalij MJ, Jukema JW, Van Der Wall EE, Bax JJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Formenti A, Annoni AD, Ballerini G, Fiorentini C, Bartorelli AL, Pepi M, Ho KT, Yong QW, Chua KC, Panknin C, Roos CJ, Van Werkhoven JM, Schuijf JD, Van Velzen JE, Witkowska-Grzeslo AJ, Boogers MJ, Kroft LJ, De Roos A, Jukema JW, Bax JJ, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, De Graaf FR, Schuijf JD, Veltman CE, Van Werkhoven JM, Van Velzen JE, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Mut F, Giubbini R, Lusa L, Massardo T, Iskandrian A, Dondi M, Sato A, Kakefuda Y, Ojima E, Adachi T, Atsumi A, Ishizu T, Seo Y, Hiroe M, Aonuma K, Kruk M, Pracon R, Kepka C, Pregowski J, Kowalewska A, Pilka M, Opolski M, Michalowska I, Dzielinska Z, Demkow M, Stoll V, Sabharwal N, Chakera A, Ormerod O, Fernandes H, Bernardes M, Martins E, Oliveira P, Vieira T, Terroso G, Oliveira A, Faria T, Ventura F, Pereira J, Fukuzawa S, Inagaki M, Sugioka J, Ikeda A, Okino S, Maekawa J, Uchiyama T, Kamioka N, Ichikawa S, Afshar M, Alvi R, Aguilar N, Ippili R, Shaqra H, Bella J, Bhalodkar N, Dos Santos A, Daicz M, Cendoya LO, Marrero HG, Casuscelli J, Embon M, Vera Janavel G, Duronto E, Gurfinkel EP, Cortes CM, Takeishi Y, Nakajima K, Yamasaki Y, Nishimura T, Hayes Brown K, Collado F, Alhaji M, Green J, Alexander S, Vashistha R, Jain S, Aldaas F, Shanes J, Doukky R, Ashikaga K, Akashi YJ, Uemarsu M, Kamijima R, Yoneyama K, Omiya K, Miyake Y, Brodov Y, Venuraju S, Yerramasu A, Raval U, Lahiri A, Berezin A, Seden V, Koretskaya E, Berezin A, Panasenko TA, Matsuo S, Nakajima K, Kinuya S, Veltman CE, Boogers MJ, Chen J, Delgado V, Van Bommel RJ, Van Der Hiel B, Dibbets-Schneider P, Van Der Wall EE, Garcia EV, Bax JJ, Rutten-Vermeltfoort I, Gevers MMJ, Verhoeven B, Dijk Van AB, Raaijmakers E, Raijmakers PGHM, Engvall JE, Gjerde M, De Geer J, Olsson E, Quick P, Persson A, Mazzanti M, Marini M, Pimpini L, Perna GP, Marciano C, Gargiulo P, Galderisi M, D'amore C, Savarese G, Casaretti L, Paolillo S, Cuocolo A, Perrone Filardi P, Thompson RC, Al-Amoodi M, Thompson EC, Kennedy K, Bybee KA, Mcghie AI, O'keefe JH, Bateman TM, Van Der Palen RLF, Mavinkurve-Groothuis AM, Bulten B, Bellersen L, Van Laarhoven HWM, Kapusta L, De Geus-Oei LF, Pollice PP, Bonifazi MB, Pollice FP, Clements IP, Hodge DO, Scott CG, Daou D, Tawileh M, Coaguila C, De Ville De Goyet M, Brichard B, Pirotte T, Moniotte S, Tio RA, Elvan A, Dierckx RAIO, Slart RHJA, Furuhashi T, Moroi M, Hase H, Joki N, Masai H, Kunimasa T, Nakazato R, Fukuda H, Sugi K, Kryczka K, Kaczmarska E, Kepka C, Dzielinska Z, Petryka J, Mazurkiewicz L, Kruk M, Pregowski J, Demkow M, Ruzyllo W, Smanio P, Vieira Segundo E, Siqueira M, Kelendjian J, Ribeiro J, Alaca J, Oliveira M, Alves F, Peovska I, Maksimovic J, Vavlukis M, Kostova N, Pop Gorceva D, Majstorov V, Zdraveska M, Hussain S, Djearaman M, Hoey E, Morus L, Erinfolami O, Macnamara A, Kepka C, Kruk M, Pregowski J, Opolski MP, Pracon R, Michalowska I, Ruzyllo W, Witkowski A, Demkow M, Berti V, Ricci F, Gallicchio R, Acampa W, Cerisano G, Vigorito C, Sciagra' R, Pupi A, Cuocolo A, Nasr GM, Sliem H, Collado FM, Alhaji M, Schmidt S, Maheshwari A, Kiriakos R, Hayes Brown K, Vashistha R, Mwansa V, Shanes J, Doukky R, Ljubojevic S, Sedej S, Holzer M, Marsche G, Marijanski V, Kockskaemper J, Pieske B, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Ochoa JM, Ricalde A, Alexanderson G, Meave A, Mohani A, Khanna P, Liu Y, Sinusas A, Lee F, Pinas VA, Van Eck-Smit BLF, Verberne HJ, Lammertsma AA, De Bruin CM, Windhorst AD, Pena H, Guilhermina G, Wilk M, Srour Y, Godinho F, Jimenez-Angeles L, Ruiz De Jesus O, Yanez-Suarez O, Vallejo E, Reyes E, Chan M, Hossen ML, Underwood SR, Karu A, Bokhari S, Aguade-Bruix S, Cuberas-Borros G, Pineda V, Gracia-Sanchez LM, Pizzi MN, Garcia-Burillo A, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Zavadovskiy K, Lishmanov YU, Saushkin W, Kovalev I, Chernishov A, Pontone G, Andreini D, Cortinovis S, Bertella E, Mushtaq S, Annoni A, Formenti A, Bartorelli AL, Fiorentini C, Pepi M, Tarkia M, Saraste A, Saanijoki T, Oikonen V, Savunen T, Green MA, Strandberg M, Teras M, Knuuti J, Roivainen A, Gaeta MC, Fernandez Y, Artigas C, Deportos J, Geraldo L, Flotats A, La Delfa V, Carrio I, Wong YY, Lubberink M, Ruiter G, Knaapen P, Raijmakers P, Laarse WJ, Vonk-Noordegraaf A, Izquierdo Gomez MM, Lacalzada Almeida J, Barragan Acea A, De La Rosa Hernandez A, Juarez Prera R, Blanco Palacios G, Bonilla Arjona JA, Jimenez Rivera JJ, Iribarren Sarrias JL, Laynez Cerdena I, Dedic A, Rossi A, Ten Kate GJR, Dharampal A, Moelker A, Galema TW, Mollet N, De Feyter PJ, Nieman K, Andreini D, Pontone G, Mushtaq S, Formenti A, Bertella E, Annoni A, Ballerini G, Fiorentini C, Pepi M, Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Trabattoni D, Bertella E, Annoni A, Formenti A, Fiorentini C, Pepi M, Broersen A, Frenay M, Boogers MM, Kitslaar PH, Van Velzen JE, Schuijf JD, Dijkstra J, Bax JJ, Reiber JHC, Pontone G, Andreini D, Mushtaq S, Bertella E, Annoni DA, Muratori M, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Dharampal AS, Weustink AC, Rossi A, Neefjes LAE, Papadopoulou SL, Chen C, Mollet NRA, Boersma EH, Krestin GP, De Feyter PJ, Purvis JA, Sharma D, Hughes SM, Zafrir N, Maddahi J, Berman DS, Taillefer R, Udelson J, Devine M, Lazewatsky J, Bhat G, Washburn D, Yerramasu A, Patel D, Mazurek T, Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F, Fukuda H, Moroi M, Masai H, Kunimasa T, Nakazato R, Furuhashi T, Sugi K, Harbinson MT, Wells G, Dougan J, Borges-Neto S, Phillips H, Farzaneh-Far A, Starr Z, Shaw LK, Fiuzat M, O'connor C, Henzlova M, Duvall WL, Levine A, Baber U, Croft L, Sahni S, Sethi S, Hermann L, Allam AH, Wann LS, Thompson RC, Nureldin A, Gomaa A, Badr I, Soliman MAT, Hany HAR, Sutherland ML, Thomas GS, Yiu KH, Schuijf J, Van Werkhoven JM, De Graaf F, Pazhenkottil A, Jukema JW, Bax JJ, De Roos A, Kroft LJ, Kaufmann PA, Kroner ESJ, Van Velzen JE, Boogers MJ, Siebelink HMJ, Schalij MJ, Kroft LJ, De Roos A, Reiber JH, Schuijf JD, Bax JJ, Ayub M, Naveed T, Azhar M, Van Tosh A, Faber TL, Votaw JR, Reichek N, Pulipati B, Palestro C, Nichols KJ, Einstein AJ, Khawaja T. Abstracts. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
37
|
Smit EF, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, van der Veldt AA. Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Luurtsema G, Verbeek GL, Lubberink M, Lammertsma AA, Dierckx R, Elsinga P, Windhorst AD, van Waarde A. Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages. Curr Top Med Chem 2011; 10:1820-33. [PMID: 20645915 DOI: 10.2174/156802610792928013] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Accepted: 02/12/2010] [Indexed: 11/22/2022]
Abstract
P-glycoprotein (P-gp) is a drug efflux transporter with broad substrate specificity localized in the blood-brain barrier and in several peripheral organs. In order to understand the role of P-gp in physiological and patho-physiological conditions, several carbon-11 labelled P-gp tracers have been developed and validated. This review provides an overview of the spectrum of radiopharmaceuticals that is available for this purpose. A short overview of the physiology of the blood-brain barrier in health and disease is also provided. Tracer kinetic modelling for quantitative analysis of P-gp function and expression is highlighted, and the advantages and disadvantages of the various tracers are discussed.
Collapse
Affiliation(s)
- G Luurtsema
- University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
van der Veldt AA, Lubberink M, Comans EF, Greuter HN, van Lingen A, Rizvi S, Windhorst AD, Smit E, Hendrikse N, Lammertsma AA. PET imaging of [ 11C]docetaxel uptake and tumor perfusion in lung cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Timmer SAJ, Lubberink M, Germans T, Götte MJW, ten Berg JM, ten Cate FJ, van Rossum AC, Lammertsma AA, Knaapen P. Potential of [11C]acetate for measuring myocardial blood flow: Studies in normal subjects and patients with hypertrophic cardiomyopathy. J Nucl Cardiol 2010; 17:264-75. [PMID: 20039151 DOI: 10.1007/s12350-009-9181-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2009] [Accepted: 12/04/2009] [Indexed: 11/27/2022]
Abstract
BACKGROUND Measuring the rate of clearance of carbon-11 labelled acetate from myocardium using positron emission tomography (PET) is an accepted technique for noninvasively assessing myocardial oxygen consumption. Initial myocardial uptake of [(11)C]acetate, however, is related to myocardial blood flow (MBF) and several tracer kinetic models for quantifying MBF using [(11)C]acetate have been proposed. The objective of this study was to assess these models. METHODS Eighteen healthy subjects and 18 patients with hypertrophic cardiomyopathy (HCM) were studied under baseline conditions with [(11)C]acetate and [(15)O]water. Four previously reported methods, including single- and multi-tissue compartment models, were used to calculate MBF from the measured [(11)C]acetate rate of influx K (1) and the (previously) reported relationship between K (1) and MBF. These MBF values were then compared with those derived from corresponding [(15)O]water studies. RESULTS For all models, correlations between [(11)C]acetate and [(15)O]water-derived MBF ranged from .67 to .86 (all P < .005) in the control group and from .73 to .85 (all P < .001) in the HCM group. Two out of four models systematically underestimated perfusion with [(11)C]acetate, whilst the third model resulted in an overestimation. The fourth model, based on a simple single tissue compartment model with spillover, partial volume and recirculating metabolite corrections, resulted in a regression equation with a slope of near unity and an Y-intercept of almost zero (controls, K(1) = .74[MBF] + .09, r = .86, SEE = .13, P < .001 and HCM, K(1) = .89[MBF] + .03, r = .85, SEE = .12, P < .001). CONCLUSION [(11)C]acetate enables quantification of MBF in fairly good agreement with actual MBF in both healthy individuals and patients with HCM. A single tissue compartment model with standardized correction for recirculating metabolites and with corrections for partial volume and spillover provided the best results.
Collapse
Affiliation(s)
- S A J Timmer
- Department of Nuclear Medicine & PET Research, VU University Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
de Haan S, Knaapen P, Beek AM, de Cock CC, Lammertsma AA, van Rossum AC, Allaart CP. Risk stratification for ventricular arrhythmias in ischaemic cardiomyopathy: the value of non-invasive imaging. Europace 2010; 12:468-74. [DOI: 10.1093/europace/euq064] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Luurtsema G, Boellaard R, Greuter HNJM, Rijbroek A, Takkenkamp K, de Geest FGM, Buijs FL, Harry Hendrikse N, Franssen EJF, van Lingen A, Lammertsma AA. Pharmaceutical preparation of oxygen-15 labelled molecular oxygen and carbon monoxide gasses in a hospital setting. J Clin Pharm Ther 2010; 35:63-9. [DOI: 10.1111/j.1365-2710.2009.01032.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Abstract
PURPOSE Regular monitoring of PET scanner performance is mandatory to assure quality of acquired data. While extensive performance measurements include many scanner characteristics such as resolution, count rate, uniformity, sensitivity, and scatter fraction (SF), most daily QC protocols are limited to uniformity and sensitivity measurements. These measurements may be too insensitive to detect more subtle drifts in detector gains that could lead to reduced detection of primary and increased detection of scattered events. Current methods to measure SF, such as those prescribed by the NEMA protocols (SF-NEMA), however, require specially designed phantoms and are too cumbersome to be performed on a daily basis. METHODS In this study, a simple and versatile method to determine SF is described. This method (SF-DAILY) does not require additional measurements, making it suitable for daily QC. The method was validated for four different scanners by comparing results with those obtained with the NEMA 1994 protocol. RESULTS For all scanner types and acquisition modes, excellent agreement was found between SF-NEMA and SF-DAILY. CONCLUSIONS The proposed method is a very practical and valuable addition to current daily QC protocols. In addition, the method can be used to accurately measure SF in phantoms with other dimensions than the NEMA phantom.
Collapse
Affiliation(s)
- H W de Jong
- Department of Radiology and Nuclear Medicine, University Medical Centre, P. O. Box 85500, 3508 GA, Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
44
|
Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel B. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 2009; 73:2079-85. [DOI: 10.1212/wnl.0b013e3181c679cc] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
Kropholler MA, Boellaard R, Elzinga EH, van der Laken CJ, Maruyama K, Kloet RW, Voskuyl AE, Dijkmans BAC, Lammertsma AA. Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis. Eur J Nucl Med Mol Imaging 2008; 36:624-31. [DOI: 10.1007/s00259-008-0987-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2008] [Accepted: 10/09/2008] [Indexed: 10/21/2022]
|
46
|
Bartels AL, van Berckel BNM, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord 2008; 14:505-8. [PMID: 18325822 DOI: 10.1016/j.parkreldis.2007.11.007] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2007] [Revised: 11/27/2007] [Accepted: 11/29/2007] [Indexed: 10/22/2022]
Abstract
The cause of Parkinson's disease (PD) is unknown. Genetic susceptibility and exposure to environmental toxins contribute to specific neuronal loss in PD. Decreased blood-brain barrier (BBB) P-glycoprotein (P-gp) efflux function has been proposed as a possible causative link between toxin exposure and PD neurodegeneration. In the present study BBB P-gp function was investigated in vivo in 10 early stage PD patients and 8 healthy control subjects using (R)-[(11)C]-verapamil and PET. Cerebral volume of distribution (V(d)) of verapamil was used as measure of P-gp function. Both region of interest (ROI) analysis and voxel analysis using statistical parametric mapping (SPM) were performed to assess regional brain P-gp function. In addition, MDR1 genetic polymorphism was assessed. In the present study, a larger variation in V(d) of (R)-[(11)C]-verapamil was seen in the PD group as compared to the control group. However, decreased BBB P-gp function in early stage PD patients could not be confirmed.
Collapse
Affiliation(s)
- A L Bartels
- Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
| | | | | | | | | | | |
Collapse
|
47
|
Geuze E, van Berckel BNM, Lammertsma AA, Boellaard R, de Kloet CS, Vermetten E, Westenberg HGM. Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder. Mol Psychiatry 2008; 13:74-83, 3. [PMID: 17667960 DOI: 10.1038/sj.mp.4002054] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Gamma-aminobutyric acid (GABA(A)) receptors are thought to play an important role in modulating the central nervous system in response to stress. Animal data have shown alterations in the GABA(A) receptor complex by uncontrollable stressors. SPECT imaging with benzodiazepine ligands showed lower distribution volumes of the benzodiazepine-GABA(A) receptor in the prefrontal cortex of patients with post-traumatic stress disorder (PTSD) in one, but not in another study. The objective of the present study was to assess differences in the benzodiazepine-GABA(A) receptor complex in veterans with and without PTSD using [(11)C]flumazenil and positron emission tomography (PET). Nine drug naive male Dutch veterans with deployment related PTSD and seven male Dutch veterans without PTSD were recruited, and matched for age, region and year of deployment. Each subject received a [(11)C]flumazenil PET scan and a structural magnetic resonance imaging scan. Dynamic 3D PET scans with a total duration of 60 min were acquired, and binding in template based and manually defined regions of interest (ROI) was quantified using validated plasma input and reference tissue models. In addition, parametric binding potential images were compared on a voxel-by-voxel basis using statistical parametric mapping (SPM2). ROI analyses using both template based and manual ROIs showed significantly reduced [(11)C]flumazenil binding in PTSD subjects throughout the cortex, hippocampus and thalamus. SPM analysis confirmed these results. The observed global reduction of [(11)C]flumazenil binding in patients with PTSD provides circumstantial evidence for the role of the benzodiazepine-GABA(A) receptor in the pathophysiology of PTSD and is consistent with previous animal research and clinical psychopharmacological studies.
Collapse
Affiliation(s)
- E Geuze
- Research Centre-Military Mental Healthcare, Ministry of Defense, Utrecht, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
48
|
Elzinga EH, van der Laken CJ, Comans EFI, Lammertsma AA, Dijkmans BAC, Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007; 9:357-60. [PMID: 17902022 PMCID: PMC2040173 DOI: 10.1007/s11307-007-0113-4] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Purpose Previous positron emission tomography (PET) studies have shown increased 2-deoxy-2-[18F]fluoro-d-glucose (FDG) uptake in joints of patients with osteoarthritis (OA) and inflamed joints of patients with rheumatoid arthritis (RA). This study compares FDG uptake in joints of RA and OA patients and FDG-uptake with clinical signs of inflammation. Procedures FDG-PET scans of hands and wrists were performed in patients with RA and primary OA. PET data were compared with clinical data. Results 29% of RA joints and 6% of OA joints showed elevated FDG-uptake. The level of uptake in PET-positive OA joints was not significantly different from that in RA joints. The majority of PET results of RA joints corresponded with clinical findings. Clinical synovitis was found some OA joints with FDG-uptake. Conclusions FDG-uptake was observed in the majority of clinically inflamed RA joints and in a few OA joints with no significant difference in uptake level. The latter may be due to secondary synovitis.
Collapse
Affiliation(s)
- E H Elzinga
- Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands.
| | | | | | | | | | | |
Collapse
|
49
|
Marques KM, Knaapen P, Boellaard R, Lammertsma AA, Westerhof N, Visser FC. Microvascular Function in Viable Myocardium After Chronic Infarction Does Not Influence Fractional Flow Reserve Measurements. J Nucl Med 2007; 48:1987-92. [DOI: 10.2967/jnumed.107.044370] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
50
|
Rijbroek A, Wisselink W, Vriens EM, Barkhof F, Lammertsma AA, Rauwerda JA. Asymptomatic Carotid Artery Stenosis: Past, Present and Future. Eur Neurol 2006; 56:139-54. [PMID: 17035702 DOI: 10.1159/000096178] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2006] [Accepted: 07/17/2006] [Indexed: 11/19/2022]
Abstract
BACKGROUND The role of carotid endarterectomy (CEA) for asymptomatic carotid artery stenosis (aCAS) remains a matter of debate. It seems that not only the degree of stenosis, but also other factors have to be taken in account to improve patient selection and increase the benefit of CEA for aCAS. METHODS AND RESULTS The literature pertaining aCAS was reviewed in order to describe the natural history, risk of stroke and benefit of CEA for patients with aCAS in regard to several factors. CONCLUSION The benefit of CEA for aCAS is low. Current factors influencing the indication for CEA are severity of stenosis, age, contralateral disease, stenosis progression to >80%, gender, concomitant operations and life expectancy. To improve patient selection investigations will concentrate on plaque characteristics and instability and cerebral hemodynamics and metabolism.
Collapse
Affiliation(s)
- A Rijbroek
- Department of General Surgery, Kennemer Gasthuis, NK-2000 AK Haarlem, The Netherlands.
| | | | | | | | | | | |
Collapse
|